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Abstract
Advanced stage ovarian cancer is the most lethal gynecologic malignancy. No major
improvement on patient survival has been achieved in the past decade. Therefore,
identification of predictive or prognostic markers and further understanding of the molecular
mechanisms in ovarian cancer progression are of paramount importance.
While cancer cells have always been the targets for the identification of prognostic and
predictive markers, the potential for developing new diagnosis and treatments based on the
tumor supporting stromal microenvironment is relatively unexplored. Using transcriptome
profiling analysis on microdissected stromal and epithelial components of normal and malignant
ovarian tissues, we identified a gene signature in the fibroblastic stromal component of the
tumor tissue. Among the differentially expressed genes identified in microdissected cancer
associated fibroblasts, microfibrillar associated protein 5 (MFAP5), which showed 10 folds
increase in expression showed significant association with poorer overall survival in patients
with high grade serous ovarian cancer. In addition, we identified a positive correlation between
stromal MFAP5 expression and intratumor microvessel density, suggested a pro-angiogenic
role of MFAP5. This study aims at delineating the functional roles and mechanisms by which
stromal MFAP5 modulates ovarian tumor progression and angiogenesis and investigating the
potential of targeting stromal MFAP5 as therapy for ovarian cancer.
Functional studies demonstrated that MFAP5 stimulated motility and invasion potential
of ovarian cancer cells and microvascular endothelial cells through the binding of αvβ3 integrin
receptor. In vivo, targeting stromal MFAP5 using siRNA incorporated chitosan nanoparticles
iv

significantly reduced tumor growth, metastasis and intratumoral microvessel density. Further,
pathway analyses and western blot analyses demonstrated that CAF-derived MFAP5
modulates ovarian cancer cell motility and invasion potential through the calcium dependent
FAK/CREB/TNNC1 signaling pathway and MFAP5 enhanced endothelial cell motility potential
and permeability via focal adhesion and stress fiber formation by activating the calcium
dependent FAK/ERK/LPP signaling pathway. Finally, monoclonal anti-MFAP5 antibodies were
developed. These antibodies demonstrated inhibitory effects on tumor growth and improved
paclitaxel bioavailability via the reduction of intratumoral microvessel leakiness.
To conclude, our results demonstrated the important roles of MFAP5 in promoting
ovarian tumor progression and the potential of targeting stromal MFAP5 as a novel therapeutic
approach for ovarian cancer.
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1. Rationale and significance
In the United States, researchers have estimated the diagnosis of 21,290 new cases of
and 14,180 deaths owing to ovarian cancer in 2015,1 making it the most lethal gynecologic
malignancy. Being the most common histological subtype of ovarian cancers, high-grade
serous ovarian cancer (HGSOC) is often regarded as the silent killer as HGSOC is usually
diagnosed at late stage with significantly decreased 5-year survival rate. Ovarian cancer is
notable for initial chemotherapy sensitivity using combination platinum and taxane-based
therapy following debulking surgery. However, the vast majority of ovarian cancer patients will
have their disease recur within 12 - 24 months after initial diagnosis. Recurring tumors are
frequently resistant to chemotherapy. Without an effective treatment option, patients will die of
progressive chemotherapy-resistant tumor.
To improve treatment effectiveness and survival of ovarian cancer patients, we are
desperately in need of new therapeutic targets, which can be used to develop new treatment
regimen. While most current treatment options and therapeutic agents are targeting the biology
of ovarian cancer cells, the importance of tumor supportive microenvironment must not be
overlooked. The tumor microenvironment, composed primarily of fibroblasts, endothelial cells,
lymphocytic infiltrates and extracellular matrix proteins, can directly affect cancer cell growth,
migration, and differentiation,2 thereby presenting an unique aspect of diagnosing and treating
cancer. Fibroblasts are primarily responsible for producing the structural components of the
stromal microenvironment, which is mostly composed of collagen type I, II and IV as well as
fibronectin.2 Fibroblasts also produce secreted factors such as cytokines and growth factors,
which maintain normal tissue homeostasis by signaling to other cell components in the stroma,
such as immune, fat, vascular, smooth muscle and epithelial cells. Fibroblasts in the tumor
stromal microenvironment exhibit altered secretion of extracellular proteins as well as paracrine
growth factors, which modify the niche of tumor microenvironment and promote cancer cell
proliferation, migration, and invasion potentials. Previous transcriptome profiling studies
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identified prognostic gene signatures for advanced HGSOC.3-5 However, large-scale
transcriptome profiles generated using the stromal component of ovarian tumors are lacking,
and the prognostic significance of stromal gene expression remains largely unknown.
To address the gap of knowledge, we performed transcriptome profiling on
microdissected ovarian cancer associated fibroblasts (CAFs) (N=33) from patients with
HGSOC. When their expression profiles were compared against those of microdissected
normal ovarian fibroblasts (N=8), normal ovarian surface epithelial cells (N=6) and ovarian
cancer cells (N=33), we identified a list of differentially expressed genes in CAFs. Among them,
MFAP5 is significantly upregulated for 10 folds and follow up survival study suggested it as a
poor prognostic marker for HGSOC. In addition, we identified a positive correlation between
stromal MFAP5 expression levels and CD31 positive microvessel density in ovarian tumor
samples, suggested a pro-angiogenic role of stromal MFAP5.
Tumor-induced angiogenesis is a process by which growing solid tumors produce
diffusible angiogenic factors that induce host capillary endothelial cells to proliferate, migrate
and form new vessels.6-9 In addition, microvessel density has been shown to be a prognostic
marker for different types of tumors.10-13 Molecules or markers related to angiogenesis including
VEGF and FGF have been extensively studied.14 Multiple therapeutic agents targeting these
proteins, such as the anti-VEGF monoclonal antibody, bevacizumab, and various FGF
inhibitors have been developed.14 However, drug toxicity and their modest therapeutic efficacy
remain outstanding concerns.14,15 Toxicity of these antiangiogenic agents is likely due to the
fact that a majority of these pro-angiogenic molecules being targeted are expressed at high
levels by normal tissues and organs.16 Therefore, finding new molecular targets that can
improve therapeutic benefit from anti-angiogenic strategies are of paramount importance. In
addition, identifying new targets from the tumor stroma may compensate the deficiency of
current agents that are designed to target tumor-derived factors only.
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Based on our preliminary findings, this proposed study aims at delineating the functional
roles of CAFs-derived MFAP5 from two different angles: First, the effects of MFAP5 on ovarian
cancer progression through modulation of the aggressive phenotypes of ovarian cancer cells,
and second, the effects of MFAP5 on promoting tumor growth by mediating angiogenesis.
Uncovering the roles of MFAP5 in ovarian tumor progression and dissecting the molecular
signaling mechanisms behind will provide us with the strong foundation for the final aim of the
proposed study: To evaluate the potential of MFAP5 targeted therapy in ovarian cancer
treatment.
In short term, this study will provide insights into the importance of microenvironment in
cancer progression. Including MFAP5 as a prognostic marker for advanced stage HGSOC
could benefit disease diagnosis and prediction of clinical outcomes. In long term, MFAP5’s
tumor promoting and pro-angiogenic roles suggested its potential as a novel therapeutic target.
Besides targeting MFAP5 alone, since therapeutic approaches that target both cancer cells and
the surrounding tumor-supporting microenvironment could potentially be more effective,
MFAP5 targeted therapy can be used in synergy with standard cytotoxic chemotherapy agents
to enhance treatment effectiveness, as well as in combination with current anti-angiogenic
therapy which targets tumor-derived angiogenic factors to improve therapeutic benefit from
anti-angiogenic strategies. Furthermore, the stratification of patients according to stromal
MFAP5 expression will provide the basis for new trial designs for new therapeutic agents
targeting MFAP5 in patients with HGSOC. This effort will form the basis of “personalized”
medicine for ovarian cancer patients. Last but not least, predictive markers will enable
physicians to identify patients who will not respond to newly developed therapy. This would
allow the avoidance of unnecessary toxicity and the opportunity to be treated with experimental
therapy.
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Taken together, our understanding of the oncogenic role of stromal MFAP5 in ovarian
cancer will certainly provide a novel insight into stromal markers, which will definitely reflect on
the strategies for innovative treatment of ovarian cancer.

2. Hypothesis
Using transcriptome profiling analysis on microdissected stromal and epithelial
components of normal and malignant ovarian tissues, we identified a gene signature in the
fibroblastic stromal component of the tumor tissue. Among the differentially expressed genes
identified in microdissedcted cancer associated fibroblasts (CAFs), microfibrillar associated
protein 5 (MFAP5), which showed 10 folds increase in expression and significantly associated
with poorer overall survival in patients with HGSOC was selected for further studies. Our
immunostaining data showed that a high level of stromal MFAP5 expression is significantly
correlated to the density of intra-tumor CD31 positive microvessels, suggested that MFAP5
may play a role in tumor angiogenesis. Based on the immunostaining and survival analysis
results, we hypothesize that CAFs-derived MFAP5 promotes ovarian cancer progression
by enhancing the aggressiveness of cancer cells and increasing tumor angiogenesis.
Hence, targeting MFAP5 in the tumor microenvironment may be a new modality in
ovarian cancer treatment.

3. Specific aims
I)

To evaluate the role of CAF derived MFAP5 on ovarian cancer cell growth,

motility and invasion potential and delineate the underlying signaling mechanism. The
effects of MFAP5 on ovarian cancer cell proliferation, motility and invasion potential were
evaluated by treating cancer cells with recombinant MFAP5 protein and silencing stromal
5

mfap5 in animal models. The underlying molecular mechanism of MFAP5-modulated tumor
progression was delineated by transcriptome profiling and pathway analysis.
II) To evaluate the angiogenic role of CAF derived MFAP5 in ovarian cancer
microenvironment using microvascular endothelial cells and mouse models. We treated
endothelial cells with exogeneous MFAP5 and study its effect on cell proliferation, migration
and invasion potentials in vitro. We also performed in vivo angiogenesis assay by injecting
MFAP5 supplemented Matrigel into mice to study the angiogenic effect of MFAP5 in vivo.
III) To develop MFAP5 targeted therapeutic agents for ovarian cancer treatment.
Monoclonal anti-MFAP5 antibodies were developed and the efficacy of abrogating the proangiogenic and tumor-promoting effects of MFAP5 in vitro and in vivo for ovarian cancer
treatment was evaluated.

4. Epithelial ovarian cancer
Epithelial ovarian cancer is the fourth commonest cause of female cancer death.17 In
the United States, researchers have estimated the diagnosis of 21,290 new cases of and
14,180 deaths owing to ovarian cancer in 2015,1 making it the most lethal gynecologic
malignancy. The disease typically presents in postmenopausal women, with a few months of
abdominal discomfort, bloating, gas, nausea and urinary urgency, which are usually mistaken
for gastrointestinal problems at the early stage.18,19 The high mortality rate is due to the late
presentation of the disease, usually when it is widely metastatic within the abdomen and
caused abdominal pain or distension (International Federation of Gynecology and Obstetrics
[FIGO] stage III).20,21 Although the 5 years survival rate for stage I ovarian cancer is >90%,
most patients (~75%) present with advanced stage (III/IV) tumors have a 5 years survival rate
of a dismal 30%.22
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A. Histopathology and molecular pathology
It has been claimed that ovarian cancer is a general term for a variety of molecularly
and histologically distinct diseases that simply share an anatomical location.23 Ovarian cancers
consist of 4 major histological subtypes (Fig. 1), which have been shown to associate with
different mutations (Fig. 2).17

Fig. 1: The major histologic subtypes of ovarian carcinoma. Serous carcinomas resemble
fallopian tube epithelium, endometriod carcinomas resemble endometrial glands, and mucinous
carcinomas resemble endocervical epithelium. Photographs show representative tumor sections
stained with hematoxylin and eosin. The shaded circle represents the general anatomical
location from which ovarian carcinomas are thought to arise. The pink and blue entities within the
cross-sected ovary represent maturing ovarian follicles. (Alison M. Karst and Ronny Drapkin,
“Ovarian Cancer Pathogenesis: A Model in Evolution,” Journal of Oncology, vol. 2010, Article ID
932371, 13 pages, 2010. doi:10.1155/2010/932371)
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Fig. 2: Epithelial subtypes of ovarian cancer and associated mutations. (Reprinted from
The Lancet 384 (9951), Jayson, G.C., Kohn, E.C., Kitchener, H.C. & Ledermann, J.A.,
Ovarian cancer, 1376-88 (2014), with permission from Elsevier)
High-grade serous ovarian cancers are derived from the surface of the ovary and/ or the
distal fallopian tube.23 It is characterized by nearly universal p53 gene abnormalities,24,25 DNA copy
number abnormalities, but few distinct and recurrent mutations.5 Most hereditary high-grade serous
ovarian cancer associated to deleterious mutations in BRCA1 and BRCA2. Approximately 70% of
ovarian cancer patients will be diagnosed with high-grade serous ovarian cancer, and these women
have a substantially worse outcome than the outcome of those with early stage disease. It is also
characterized by the initial chemosensitivity with subsequent acquisition of increasing resistance at
each recurrence.17
Low-grade serous and endometrioid ovarian cancer shows more indolent behavior and
they have low response rates to cytotoxic drugs and hormonal agents. KRAS mutation is prevalent in
low grade serous ovarian cancer and PI3KCA mutation is common in endometrioid subtype of ovarian
cancer.
Clear cell ovarian cancers are derived from endometriosis and frequently bear the ARID1A
gene mutations.26 They are characterized by the uniform high-grade nuclear features with clear
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cytoplasm and poor response to chemotherapy.
Lastly, mucinous ovarian cancers are most commonly diagnosed at an early stage. Invasive
mucinous ovarian cancers are mostly metastases from the gastrointestinal tract, including the colon,
appendix or stomach, to the ovary. Nearly all cases of this rare type of cancer have KRAS mutation
and a high frequency of HER2 amplication.17,23
B. Treatments for ovarian cancer
Depending on the stage of cancer, standard of care for epithelial ovarian cancer is surgery and
platinum-based cytotoxic chemotherapy. Surgical options include: total hysterectomy, bilateral
salpingo-oophorectomy, tumor debulking and omentectomy.27 When optimal surgical debulking is not
feasible, the use of neoadjuvant chemotherapy is widely accepted and supported by large randomized
trials.28,29 In the past 20 years, the global standard for first-line chemotherapy remains to be
carboplatin and paclitaxel.17,30-32 The median progression free survival (PFS) of advanced ovarian
cancer is about 18 months and patients with the worst prognosis are those develop platinum-resistant
disease.17
In seek of new treatment regimens, two new treatment strategies were proposed in recent
years. First, poly (ADP-ribose) polymerase (PARP) inhibitors for ovarian cancers harbor BRCA1 or
BRCA2 mutations. The mechanism of this chemosensitivity hinged on the crucial role that BRCA
proteins play in the repair of double-strand DNA breaks by the error-free homologous recombination.
When the gene of either BRCA protein is mutated, there is an increased reliance on the PARP singlestrand repair pathway. Therefore, for cancer cells harboring BRCA1 or BRCA2 mutations, use of
PARP inhibitors might cause significant lethality. Impressive tumor response and clinical benefit have
been observed with olaparib, a PARP inhibitor, in phase 1 trials and in randomized trials comparing
the efficacy and safety with liposomal doxorubicin in BRCA mutation carrying patients.33,34 The
second treatment approach is anti-angiogenic therapy. Rich vascular supply is vital for continuing
tumor growth and the well-known prototype of angiogenesis inducer is vascular endothelial growth
9

factor (VEGF). Preclinical studies have used a number of approaches including (1) specific VEGF
blockade with agents that interfere with VEGF binding to its receptors, such as anti-VEGF antibodies
and the “VEGF-Trap” aflibercept; (2) inhibition of VEGFR2 function by VEGFR2 antibody or receptor
tyrosine kinase inhibitors (TKIs) which inhibit the kinase domain of VEGFRs.35 Most clinical trials have
included the monoclonal anti-VEGFA antibody, bevacizumab. Particularly, GOG218 and ICON7 have
showed efficacy in using bevacizumab in addition to carboplatin and paclitaxel chemotherapy followed
by maintenance treatment in patients with FIGO stage III/IV disease with residual tumor after primary
surgery.36,37

5. Tumor microenvironment in cancer progression
The tumor microenvironment (TME), which consists of cells, soluble factors, signaling
molecules, extracellular matrix and mechanical cues that can promote neoplastic transformation and
support tumor growth, has received growing attention from cancer research scientists over the last
decade (Fig. 3).2,38 As our understanding on the contributions of the tumor microenvironment to
tumorigenesis increases, new hallmarks of cancer that are crucial to cancer phenotypes and new
frontier of therapeutic application targeting the tumor stroma have emerged.39
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Fig. 3: The primary tumor microenvironment. a) Cancer cells in primary tumors are
surrounded by a complex microenvironment comprising numerous cells including endothelial
cells of the blood and lymphatic circulation, stromal fibroblasts and a variety of bone marrowderived cells (BMDCs) including macrophages, myeloid-derived suppressor cells (MDSCs).
TIE2-expressing monocytes (TEMs) and mesenchymal stem cells (MSCs). b) Invasive
human breast cancer stained with haematoxylin and eosin in which a prominent infiltration of
leukocytes (indicated by white arrows) is evident at the invasive margin. c) Macrophages at
the invasive edge of pancreatic islet cancers express cathepsin B (green), which is
associated with loss of epithelial cadherin (red) on the neighboring cancer cells. Cell nuclei
are visualized by DAPI (blue). (Reprinted by permission from Macmillan Publishers Ltd:
Nature reviews, Cancer 9, 239-252, Joyce, J.A. & Pollard, J.W., Microenvironmental
regulation of metastasis, 2009)
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One important concept about TME is that it is a dynamic milieu, which is in constant
evolution due to continuous tissue remodeling, metabolic alterations and changes in the
recruitment of stromal cells. By changing the composition of the TME, tumors develop
resistance towards antitumor therapies and therefore combined therapy targeting both cancer
cells and the TME are being proposed.40-43

6. Cancer associated fibroblasts in tumor progression
Although the TME composed of complex variety of mesenchymal cells, notably
fibroblasts, myofibroblasts, endothelial cells, pericytes and a variety of immune cells, fibroblasts
and myofibroblasts often represent the majority of the stromal cells in various types of human
carcinomas.44 The relative proportion of stroma in advanced ovarian cancer ranges from 7% to
83% of tissue composition, with a median of 50% contribution.45
Normal fibroblasts are elongated cells residing in connective tissues and are responsible
for the synthesis and turnover of the extracellular matrix (ECM). They control and support
normal tissue homeostasis and involve in a plethora of biological processes such as wound
healing and senescence.46 Unlike normal fibroblasts, myofibroblasts residing at the tumor
margins or infiltrated into the tumor mass, also termed cancer-associated fibroblasts (CAFs),
possess greatly increased contractile ability, promote angiogenesis, and stimulate epithelial cell
growth through the production of extracellular matrix and the secretion of growth factors and
cytokines.47,48 Common upregulated CAF markers include α smooth muscle actin (α-SMA),49
stromal-derived factor 1α (SDF-1α),50 fibroblast activation protein-1α (FAP-1α),44 vimentin,51 and
fibroblast-specific protein-1 (FSP1).52 Immunohistochemistry analysis of 91 ovarian tissue
samples, including 61 epithelial ovarian cancer, 10 borderline tumors, 11 benign tumors and 9
normal ovarian tissues performed by Zhang et. al. showed almost all fibroblasts embedded in
epithelial ovarian cancer stroma were α-SMA positive and tumor cells were α-SMA negative. In
12

normal ovary tissue, α-SMA expression was detected only in vascular pericytes and weak
expression of stroma α-SMA was detected in 30% benign and borderline ovarian tumors (Fig.
4A-H).53 There was no FAP expression in normal ovarian tissues, benign tumors and borderline
tumors, while 91.8% of epithelial ovarian cancer specimens expressed FAP in the stroma. FAP
expression was rarely detected in tumor cells (Fig. 4I-L).53
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Fig. 4: The expression of α-SMA and FAP in ovarian tissues. In normal ovary tissue (A), αSMA expression detected only in blood vessel walls (arrow); in benign ovarian tumor (B) and
borderline ovarian tumor (C) there was only a very small proportion of stroma cells exhibited
weak α-SMA immunostaining (arrow); In malignant ovarian tumors (D) a large proportion of
stroma cells were α-SMA positive (arrow). A negative control without primary antibody is shown
in (E). Magnification 200X. A zoomed-in section of D is shown (F). Magnification 400X.
Quantitative analysis of the α-SMA expression in ovarian tissues showed the positive staining
area (G) and intensity (H) of α-SMA in malignant ovarian tumors stroma was more prominent
than in borderline tumors, benign tumors and normal ovarian tissues. FAP only existed in
epithelial ovarian cancer stroma (I), but not in benign tumor (J), borderline tumor (K), or normal
tissues (L). Bar = 100µm in length. **P<0.001 (ANOVA). (Reprinted from Cancer letters 303,
Zhang, Y., Tang, H., Cai, J., Zhang, T., Guo, J., Feng, D., Wang, Z., Ovarian cancer-associated
fibroblasts contribute to epithelial ovarian carcinoma metastasis by promoting angiogenesis,
lymphangiogenesis and tumor cell invasion, 47-55, (2011), with permission from Elsevier)
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“Cell plasticity” describes the ability of cells in acquiring genetic mutations, epigenetic
alterations and changes due to persistent environmental effects to alter their differentiation
status.46 Intuitively, CAFs are regarded as normal fibroblasts that have been transformed as a
result of continuous exposure to cancer cells. Indeed, CAFs often share several similarities with
normal fibroblasts morphologically and phenotypically with respect to expressions of intercellular
adhesion molecule-1 (ICAM-1), laminin and Thy-1, a surface glycoprotein that involved in cell
adhesion, migration and myofibroblastic differentiation.54-56 Regarding the transformation from
normal fibroblasts to CAFs, three models of stromal fibroblast evolution were proposed: 1)
Though relatively uncommon, genetic alterations (e.g. loss of heterozygosity and somatic
mutations) could be acquired by normal residential fibroblasts;57 2) transdifferentiation of normal
fibroblasts into CAFs without acquiring genetic alterations; and 3) differentiation from bone
marrow derived progenitor cells recruited to the tumor site (Fig. 5). Through the exchange of
intercellular secreted factors (e.g. chemokines like IL-1β and SDF-1) with other cell types in the
TME, CAFs promote tumor growth, angiogenesis, inflammation and metastasis.46,50 Therefore,
CAF-specific proteins may serve as both prognostic markers and therapeutic targets. It was
believed that targeting CAFs for cancer treatment has two advantages: 1) the ongoing functions
of CAFs is critical to the growth of nearby neoplastic cells and 2) the stromal cells are relatively
genetically stable compared to carcinoma cells which could accumulate adaptive mutations
during the course of therapy in order to acquire drug resistance.58-60
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Fig. 5: Tentative models for evolution of the stromal fibroblasts in human carcinomas.
(1) Clonal selection from a small population of fibroblasts or progenitors that have undergone
genetic alterations. (2) Trans-differentiation from, for example, pre-existing normal
fibroblasts. (3) Differentiation from bone marrow-derived progenitors. (Orimo, A. & Weinberg,
R.A. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell cycle 5, 1597-1601
(2006), reprinted by permission of Taylor & Francis LLC (http://www.tandfonline.com))
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7. Tumor angiogenesis
Like normal tissues, tumor tissues require nutrients and oxygen as well as an effective
way to eliminate metabolic wastes and carbon dioxide.61 Formation of tumor-associated
neovasculature by angiogenesis covers these needs.39,62 Pathological angiogenesis, which
ensure exponential growth of tumors, is driven by the imbalance between pro- and antiangiogenic signaling, and the activation of the “angiogenic switch” (Fig. 6).62,63 The angiogenic
switch begins with pericyte detachment and vessel dilation before the basement membrane
and extracellular matrix is degraded. This allows endothelial cells to migrate toward the
chemotactic angiogenic stimuli generated by tumor cells. Subsequently, endothelial cells
proliferate for the onset of angiogenic sprouting, new vessel formation and maturation (Fig.
7).63 However, it has been widely reported that the tumor vasculature are both structurally and
functionally abnormal compared to normal blood vessels.64,65 Structurally, tumor vessels are
often dilated with oversized diameter and the chaotic layout creates irregular blood flow. Also,
absent or immature vessels make some tumor regions impenetrable. Functionally, oversized
pores on vessel wall leak fluid from the vasculature into interstitial areas and the high interstitial
fluid pressure built up blocks transport of drugs and oxygen out of vessels to tumor tissue. In
addition, the fluidic buildup leads to swelling of tumor tissue, causing painful symptoms and
more importantly, the fluidic pressure drives tumor-generated proteins and cells toward healthy
tissues and into lymphatic system, which will increase the risk of metastasis.64 To the tumor
microenvironment, dysfunctional vessels produce conditions of low oxygen (hypoxia) and high
acidity. Hence, radiation and certain chemotherapies that require oxygen to kill tumor cells are
ineffective.66 Moreover, immune cells that might attack cancer cells cannot function in an acidic
environment and without oxygen67 and changes in gene activity caused by hypoxia might also
promote tumor cell migration toward healthy tissues.35,64
Although it is widely accepted that antiangiogenic therapies should destroy the tumor
vasculature, thereby depriving the tumor of oxygen and nutrients. The “vascular normalization”
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hypothesis proposed that rather than eliminating vessels, the judicious use of anti-angiogenic
therapy to correct the imbalance between pro- and anti-angiogenic molecules in tumor tissues,
which features the attenuation of hyperpermeability, increased vascular pericyte coverage, a
more normal basement membrane, and a resultant reduction in tumor hypoxia and interstitial
fluid pressure,65 might normalizes the tumor microenvironment and ultimately control tumor
progression and improve the efficacy of conventional therapies (Fig. 8).65,68 This might serve to
explain the clinical trial data demonstrating synergism between anti-VEGF therapy and
chemotherapy in the treatment of solid tumors.69-71
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Fig. 6: The balance hypothesis for the angiogenic switch. The normally quiescent
vasculature can be activated to sprout new capillaries (angiogenesis), a morphogenic
process controlled by an angiogenic switch mechanism. The prevailing evidence suggests
that changes in the relative balance of inducers and inhibitors of angiogenesis can activate
the switch. In some tissues, the absence of angiogenesis inducers may keep the switch off,
while in others the angiogenesis inducers are present but held in check by higher levels of
angiogenesis inhibitors. Thus, both reducing the inhibitor concentration, e.g., for TSP-1, by
loss of a tumor suppressor gene; or increasing the activator levels, e.g., for induction of
VEGF, by hypoxia, can each change the balance and activate the switch, leading to the
growth of new blood vessels. (Reprinted from Cell 86, Hanahan, D. & Folkman, J., Patterns
and emerging mechanisms of the angiogenic switch during tumorigenesis, 353-364, (1996),
with permission from Elsevier)
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Fig. 7: The classical angiogenic switch. The angiogenic switch is a discrete step in tumor
development that can occur at different stages in the tumor-progression pathway, depending
on the nature of the tumor and its microenvironment. Most tumors start growing as avascular
nodules (dormant) (a) until they reach a steady-state level of proliferating and apoptosing
cells. The Initiation of angiogenesis, or the “angiogenic switch”, has to occur to ensure
exponential tumor growth. The switch begins with perivascular detachment and vessel
dilation (b), followed by angiogenic sprouting (c), new vessel formation and maturation, and
the recruitment of perivascular cells (d), Blood-vessel formation will continue as long as the
tumor grows, and the blood vessels specifically feed hypoxic and necrotic areas of the tumor
to provide it with essential nutrients and oxygen (e). (Reprinted by permission from
Macmillan Publishers Ltd: Nature reviews, Cancer 3, 401-410, Bergers, G. & Benjamin, L.E.,
Tumorigenesis and the angiogenic switch, 2003)
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Fig. 8: Proposed role of vessel normalization in the response of tumors to
antiangiogenic therapy. (A) Tumor vasculature is structurally and functionally abnormal. It
is proposed that antiangiogenic therapies initially improve both the structure and the function
of tumor vessels. However, sustained or aggressive antiangiogenic regimens may eventually
prune away these vessels, resulting in a vasculature that is both resistant to further
treatment and inadequate for the delivery of drugs or oxygen. (B) Dynamics of vascular
normalization induced by VEGFR2 blockade. On the left is a two-photon image showing
normal blood vessels in skeletal muscle; subsequent images show human colon carcinoma
vasculature in mice at day 0 and day 3 after administration of VEGFR2-specific antibody. (C)
Diagram depicting the concomitant changes in pericyte (green) and basement membrane
(blue) coverage during vascular normalization. (D) These phenotypic changes in the
vasculature may reflect changes in the balance of pro- and antiangiogenic factors in the
tissue. (From Jain, R.K. Normalization of tumor vasculature: an emerging concept in
antiangiogenic therapy. Science 307, 58-62 (2005). Reprinted with permission from AAAS)
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8. Microfibrillar associated protein 5
Microfibrillar associated protein 5, MFAP5, also known as microfibril-associated
glycoprotein 2 (MAGP2). It is a 25-kDa extracellular glycoprotein. MFAP5 was demonstrated to
be associated with fibrillin-containing microfibrils in fetal nuchal ligament, dermis, adventitia of
aorta, glomerular mesangium and perimysium, and bound to fetal aortic smooth muscle cells and
chondrocytes.72 The C-terminal of MFAP5 containing 7 conserved cysteine residues, and was
found to interact with fibrillin-1 and -2, as well as fibulin-1, another component of elastic fibers,
suggesting that MFAP5 is an important component in the assembly of microfibrils.73 The Nterminal of MFAP5 contains an RGD motif that has been shown to mediate adhesion and
spreading of fetal bovine aortic smooth muscle cells, ear cartilage chondrocytes, arterial
endothelial cells, human skin fibroblasts and osteoblasts through the αVβ3 integrin.74 The role of
MFAP5 in cancer progression was first reported by our group that it is a prognostic factor in
advanced stage ovarian cancer with the ability to prolong tumor cell survival and stimulate
angiogenesis.75

9. Calcium signaling
Calcium is a ubiquitous intracellular signal that impacts nearly all aspect of cellular life,
from changes in protein conformations to signal transduction and its specific roles in excitability,
exocytosis, motility, apoptosis and transcription.76 Its diversity of actions lies in the versatility of
the Ca2+ signaling mechanism in terms of speed, amplitude and spatiotemporal patterning.
Generally, cells at rest have a cytoplasmic Ca2+ concentration of 100nM and maintain a 20,000fold gradient between the intracellular (~100nM) Ca2+ and extracellular (~2mM) Ca2+
concentrations. Cells are activated and calcium-mediated signal transduction takes place when
intracellular Ca2+ level raises to roughly 1000nM. Further increase in intracellular Ca2+
concentrations that exceeds the normal range of spatial and temporal boundaries may result in
22

cell death through both necrosis and apoptosis.77
To generate Ca2+ mobilizing signals, cells have to control the entry of external Ca2+ or the
release of Ca2+ from internal store, mainly from the endoplasmic reticulum (ER) (Fig. 9). For
entry from extracellular space, voltage-operated channels (VOCs), which are activated by
depolarizing membrane potentials and are mostly expressed in excitable cells, are the most wellknown players. In addition, there are calcium channels that open in response to receptor
activation called the receptor-operated channels (ROCs) and recent evidence showed that storeoperated channels (SOCs) can be activated in response to store emptying by a conformationalcoupling mechanism. Such mechanism involves direct coupling of inositol-1,4,5-triphosphate
receptors (IP3Rs) in the ER to SOCs.78-80 For Ca2+ signals that are derived from the intracellular
stores, G protein-coupled receptors (GPCRs; primarily Gq/11 subtypes) activated phospholipase
C-β (PLC-β) and tyrosine kinase receptor (TKR) activated PLC-γ are responsible for the cleaving
of phosphatidylinositol 4, 5 bisphosphate (PIP2) into 1,4,5-inositol triphosphate (IP3) and
diacylglycerol (DAG). Binding of IP3 to the IP3Rs increase cytosolic Ca2+ concentration by
allowing the diffusion of Ca2+ from the ER to the cytoplasm. On the other hand, DAG regulates
protein kinase C (PKC), as well as some Ca2+ permeable transient receptor potential (TRP)
channels directly.81 The sister intracellular channel of IP3R, the ryanodine receptors (RYRs), also
gate ER membrane Ca2+ release via the binding of cytosolic Ca2+ to RYRs. This mechanism of
Ca2+ mobilization is called calcium-induced calcium release (CICR).82
After excitation, Ca2+ is rapidly removed from the cytoplasm by various pumps and
exchangers.83,84 Plasma membrane Ca2+-ATPase (PMCA) pumps and Na+/ Ca2+ exchangers
extrude Ca2+ from the cytoplasm and the sarco-endoplasmic reticulum ATPase (SERCA) pumps
return Ca2+ to its internal stores. On the other hand, mitochondrion has a huge capacity to
accumulate Ca2+ and it sequesters Ca2+ rapidly during the development of Ca2+ signals. This
uptake of Ca2+ not only favors the shaping of both the amplitude and spatio-temporal patterns of
Ca2+ signals, it also contributes to the OFF mechanism in Ca2+ signaling.85-88 However, when
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mitochondrion is overloaded with Ca2+, the high conductance of the permeability transition pore
(PTP) might collapse the transmembrane potential of the mitochondrion, which leads to the
release of cytochrome c and the initiation of apoptosis.89 This mitochondria-mediated Ca2+
function in apoptosis might be interfered by the Ca2+ dynamics between ER and mitochondria via
death antagonists (Bcl-2 and Bcl-XL) or death agonists (Bax, Bak and Bad).77,89
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Fig. 9: Elements of the Ca2+ signaling toolkit. Cells have an extensive signaling toolkit that
can be mixed and matched to create Ca2+ signaling of widely different properties. Ca2+mobilizing signals (blue) are generated by stimuli acting through a variety of cell-surface
receptors, including G-protein (G)-linked receptors and receptor tyrosine kinase (RTK). The
signals generated include: inositol-1,4,5-triphosphate (IP3), generated by the hydrolysis of
phosphatidylinositol-4,5-biphosphate (PIP2) by a family of phospholipase C enzymes (PLC-β,
PLC-γ); cyclic ADP ribose (cADPR) and nicotinic acid dinucleotide phosphate (NAADP), both
generated from nicotinamide-adenine dinucleotide (NAD) and its phosphorylated derivative
NADP by ADP ribosyl cyclase; and sphingosine 1-phosphate (S1P), generated from
sphingosine by a sphingosine kinase. ON mechanisms (green) include plasma membrane
Ca2+ channels, which respond to transmitters or to membrane depolarization (ΔV), and
intracellular Ca2+ channels− the IP3 receptor (IP3R), ryanodine receptor (RYR), NAADP
receptor and sphingolipid Ca2+ release-mediating protein of the ER (SCaMPER). The Ca2+
released into the cytoplasm by these ON mechanisms activates different Ca2+ sensors
(purple), which augment a wide range of Ca2+ -sensitive processes (purple), depending on
cell type and context. OFF mechanisms (red) pump Ca2+ out of the cytoplasm: the Na+/ Ca2+
exchanger and the plasma membrane Ca2+ ATPase (PMCA) pumps Ca2+ out of the cell and
the sarco-endoplasmic reticulum Ca2+ ATPase (SERCA) pumps it back into the ER/SR.
(TnC, troponin C; CAM, calmodulin; MLCK, myosine light chain kinase; CAMK, Ca2+
/calmodulin-dependent protein kinase; cyclic AMP PDE, cyclic AMP phosphodiesterase;
NOS, nitric oxide synthase; PKC, protein kinase C; PYK, proline-rich kinase 2; PTP,
permeability transition pore.) (Reprinted by permission from Macmillan Publishers Ltd:
Nature reviews, Molecular cell biology 1, 11-21, Berridge, M.J., Lipp, P. & Bootman, M.D.,
The versatility and universality of calcium signalling, 2000)
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10. Roles of calcium signaling in tumor migration, invasion and metastasis
The ability to migrate is a prerequisite for cancer cells to escape the primary tumor and
disseminate to metastatic sites, which makes a tumor difficult to be eradicated and causes
mortality.39 Polarized, migrating cells exhibit a stable and transient gradient of [Ca2+], increasing
from the front of the cell to the rear for the rear-end retraction.90,91 Such retraction is supported
by myosin II contraction, which is regulated by Ca2+-dependent MLC kinase (MLCK) mediated
myosin light-chain (MLC) phosphorylation and the disassembly of adhesions at the rear of the
cell. The coordinated and dynamic formation and disassembly of cell adhesions, known as
focal adhesion turnover, with the ECM is necessary for cell migration. The components of focal
adhesion complex are regulated by Ca2+ (Fig. 10). Furthermore, migration, invasion and
metastasis of cancer cells involve multiple Ca2+ entry and release systems (Fig. 11).82
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Fig. 10: Molecular organization of focal adhesion complexes and their regulation by
Ca2+. Integrins are α- and β-transmembrane heterodimeric proteins that function as adhesion
receptors and that span the cell plasma membrane to link the extracellular matrix (ECM) with
the cytoskeleton through numerous intracellular molecules. The integrin-binding proteins
paxillin and talin recruit focal adhesion kinase (FAK) and vinculin. Cytoskeleton protein αactinin is phosphorylated by FAK, binds to vinculin, crosslinks actomyosin stress fibers and
tethers them to focal contacts. Zyxin is an α-actinin and stress fiber-binding protein that is
present in mature contacts. The membrane-associated protein tyrosine kinase SRC and the
adaptor protein p130CAS associate with focal contacts following integrin clustering. Proteins
that are transiently present at focal contacts, such as ERK2 and calpain, are not shown.
Spatially confined sustained or transient increases of Ca2+ concentration can occur in the
form of waves, sparks or flickers. Such increases can occur as a result of Ca2+ entry through
plasma membrane Ca2+-permeable channels and Ca2+ liberation from an endoplasmic
reticulum (ER) calcium store through ryanodine (RYR) and/or inositol triphosphate (IP3R)
receptor channels. These changes influence Ca2+-dependent effectors (kinases, proteases
and phosphatases), which in turn regulate focal adhesion components, this facilitating the
formation or disassembly (that is, turnover) of focal adhesions. (Reprinted by permission
from Macmillan Publishers Ltd: Nature reviews, Cancer 11, 609-618, Prevarskaya, N.,
Skryma, R. & Shuba, Y. Calcium in tumour metastasis: new roles for known actors, 2011)
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Fig. 11: Major Ca2+ entry and Ca2+ release systems involved in migration, invasion and
metastasis. Different panels represent a magnified view of the events taking place within the
areas of the migrating metastatic cell (shown in the middle of the figure). Lightning bolts
indicate activating stimuli. At the leading edge (a) membrane stretch-activated, transient
receptor potential cation channel subfamily M membrane 7 (TRPM7)-mediated Ca2+ influx
coupled to inositol triphosphate receptor (IP3R)-mediated Ca2+ release participates in the
guidance of the leading edge towards a chemoattractant. Ca2+ influx through TRPV2 promotes
migration by induction of key invasion markers, matrix metalloproteinase (MMP2), MMP9 and
cathepsin B (CTSB). Activation of TRPM7 and associated Ca2+ influx at peripheral adhesions
(b) promotes m-calpain-mediated disassembly or turnover of peripheral adhesion complexes,
thus contributing to enhanced motility. At the trailing end (c) Ca2+ influx through L-type voltagegated calcium channels (VGCCs) regulates contraction through Ca2+-dependent
phosphorylation of contractile proteins, whereas certain types of Cav3 VGCCs and TRP
members, TRPC1, TRPM8 and TRPV1, are implicated in the enhanced migration of cancer
cells through unknown effectors. Formation of focal adhesions (d) is facilitated by IP3Rmediated Ca2+ release that is stimulated through surface G protein-coupled receptors (GPCRs)
or exchange proteins directly activated by cAMP (EPAC) leading to Ca2+/calmodulindependent protein kinase II (CaMKII)-dependent focal adhesion kinase (FAK) phosphorylation
or enhanced actin assembly, respectively, by stromal interaction molecule 1 (STIM1)-calcium
release-activated calcium channel protein 1 (ORAI1)-based store-operated Ca2+ entry,
resulting in RAS and RAC activation and by secretory pathway Ca2+-ATPase (SPCA2)-ORAI1
complex-mediated constitutive Ca2+ influx. IP3R- and ryanodine receptor (RYR)-mediated Ca2+
mobilization from the endoplasmic reticulum (ER) stores also promotes cell migration in an
S100A4-dependent manner. cADPR, cyclic ADP-ribose; CICR, Ca2+-induced Ca2+ release;
DAG, diacyglycerol; ECM, extracellular matrix; LPLs, lysophospholipids; PLC, phospholipase
C. (Reprinted by permission from Macmillan Publishers Ltd: Nature reviews, Cancer 11, 609618, Prevarskaya, N., Skryma, R. & Shuba, Y. Calcium in tumour metastasis: new roles for
known actors, 2011)
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11. Troponin C type I (TNNC1)
Troponin is a complex made up of 3 individual subunits: troponin C, troponin T and
troponin I. Troponin C is a calcium-binding component of the troponin complex that triggers
skeletal and cardiac muscle contraction in response to increasing calcium levels.92,93 Under
resting intracellular Ca2+ level, troponin and tropomyosin work together to block the myosin
binding sites on actin. When calcium ions bind to troponin C, which leads to a conformational
change in troponin I, the troponin-tropomyosin complex moves and release the blockage on the
active sites. As soon as the myosin heads bind to the active sites, contraction begins.94
Interestingly, troponin C also expresses in non-muscle cells93,95 and various potential functions
for cellular locomotion, cytoplasmic streaming, and cytokinesis have been reported.93

12. LIM-containing lipoma preferred partner (LPP)
The LPP gene, located at chromosome region 3q27-q28, is the preferred translocation
partner of the HMGIC gene in a subclass of human benign mesenchymal tumors known as
lipomas.96,97 The N-terminal of the LPP contains two proline-rich stretches (DFLPPPPPPLD
and NFPPPPPLD) similar to the “FPPPP” motifs that are found in focal adhesion-associated
proteins such as zyxin and vinculin, which are believed to be involved in actin cytoskeleton
organization.98-101 These proline-rich motifs are the interacting sequence with actin regulatory
proteins of the VASP (Vasodilator-stimulated phosphoprotein) family. The C-terminal of LPP
contains three cysteine and histidine rich LIM domains, which form zinc fingers that are capable
of mediating protein-protein interactions.96,102-104 LPP localizes at focal adhesions as well as at
cell-to-cell contacts. It binds VASP and such binding is required for α-actinin anchoring into
detergent-insoluble cytoskeletal elements, suggesting that LPP may coordinate the actin
regulatory activities of VASP and α-actinin at cell-cell contacts.96,105 In addition, LPP transiently
localized in the nucleus and displayed transcriptional activation capacity, as measured by
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GAL4-based assays. In fact, a nuclear export sequence (NES) was identified in the N-terminal
region of LPP and deletion of the NES caused an accumulation of LPP in the nucleus.96,102
Taken together, LPP is a multifunctional protein that serves a role in both actin cytoskeleton
organization and gene regulation.
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Materials and Methods
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1. Tissue

samples,

microdissection,

RNA

extraction,

Affymetrix

GeneChip

hybridization, and image acquisition
Ovarian tissue samples were obtained from the ovarian cancer repository of the
Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas
MD Anderson Cancer Center under protocols approved by the MD Anderson Institutional
Review Board. All tumor samples were obtained from the primary ovarian sites of pre-treatment
cases. Microdissection was performed to isolate the stromal and epithelial components of
normal and malignant ovarian tissue for RNA extraction. Tissue sections were first fixed in 70%
ethanol and then stained with 1% methyl green to visualize the histologic features. During
microdissection, the areas of interest in the tissue sections were carefully outlined. Areas with
immune cell and blood vessel infiltration were excluded to minimize contamination. Purified
RNA samples from microdissected tissue samples were amplified, labeled, and hybridized onto
GeneChip Human Genome U133 Plus 2.0 microarrays (Affymetrix Inc., Santa Clara, CA)
according to the manufacturer’s protocol. After hybridization, arrays were washed and stained
using a Fluidics Station 450 and then scanned using a GeneChip Scanner 3000 7G (Affymetrix
Inc., Santa Clara, CA).

2. Cell lines and culture conditions
Human ovarian adenocarcinoma cell lines A224, ALST, OVCA432, and SKOV3ipluc
were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum, 2 mM
glutamine, and penicillin/streptomycin (Life Technologies Corp., Grand Island, NY). The
immortalized human normal ovarian fibroblast (NOF) cell line NOF151-hTERT and primary
CAF cells were cultured in 1:1 MCDB105/199 medium supplemented with 10% fetal bovine
serum, 10 ng/ml epidermal growth factor, and penicillin/streptomycin. Human microvascular
endothelial cells, hMEC-1, were cultured in MCDB131 medium supplemented with 10% fetal
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bovine serum, 10 mM L-glutamine, 10 ng/ml epidermal growth factor, 1 μg/mL hydrocortisone
and penicillin/streptomycin. Telomerase-immortalized microvascular endothelial cells, TIME,
were cultured in EGM-2 medium (Lonza Group Ltd., Basel, Switzerland).

3. Quantitative real-time PCR analysis
The relative expression of each target gene was calculated using the 2-ΔΔCT method to
average the CT value of the housekeeping gene for a single reference gene value. Predesigned

human

MFAP5

(Hs00185803_m1),

TNNC1

(Hs00896999_g1),

LPP

(Hs00944352_m1), cyclophilin A (Hs99999904_m1), and murine Mfap5 (Mm00489404_m1)
TaqMan gene expression assays (Life Technologies Corp., Grand Island, NY) were used in
quantitative real-time PCR analyses.

4. Western blot analysis
Protein lysates from CAFs, NOFs, ovarian cancer cells and microvascular endothelial
cells were separated on 10% sodium dodecyl sulfate NuPAGE gels under denaturing
conditions and transferred onto nitrocellulose membranes using an iBlot Western blotting
system (Life Technologies Corp., Grand Island, NY) before being incubated with primary
antibodies. Anti-human MFAP5 (#HPA010553) was purchased from Sigma-Aldrich (St. Louis,
MO). An anti-p-FAK antibody (Y861; #44-626G) was purchased from Life Technologies Corp.
(Grand Island, NY). All other antibodies, including anti-FAK (#3285), anti-PLC-γ1 (#2822), antip-PLC-γ1 (T783; #2821), anti-PKCθ (#2059), anti-p-PKCθ (T538; #9377), anti-ERK1/2 (#9102),
anti-p-ERK1/2 (T202/204; #9101), anti-CREB (#9197), anti-p-CREB (S133; #9198), anti-c-Jun
(#9165), anti-p-cJun (S63, S73, and S243; #2361, #9164, and #2994), anti-MLC2 (#8505), antip-MLC2 (T18/S19; #3674), and LPP (#3389) were purchased from Cell Signaling Technology
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Inc. (Beverly, MA). After being washed with Tris-buffered saline with Tween, the membranes
were incubated with a goat anti-rabbit IR dye-conjugated secondary antibody (LI-COR
Biosciences, Lincoln, NE). Protein bands were detected using an Odyssey infrared imaging
system (LI-COR Biosciences, Lincoln, NE). Relative normalized protein expression levels with
respect to the corresponding control were calculated based on the band intensity values
measured using the ImageJ software program (National Institutes of Health, Bethesda, MD).
The inhibitors used in pathway analyses included a PLC inhibitor (U73122; #sc-3574),
PKCθ pseudosubstrate inhibitor (#sc-3097), and ERK inhibitor II (FR180204; #sc-203945),
which were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). FAK inhibitors
(SU6656; #S9692 and PF-573228; #PZ0117) and a c-Jun inhibitor (#SP600125) were
purchased from Sigma-Aldrich Co. (St. Louis, MO), and a CBP/CREB interaction inhibitor
(#217505) was purchased from EMD Millipore Corp. (Billerica, MA).

5. Immunohistochemical analysis
Immunolocalization of MFAP5 and TNNC1 was performed using 130 and 107 FFPE
HGSOC tissue sections, respectively. Tissue sections were stained with commercially available
anti-MFAP5 (1:500; #HPA010553) and anti-TNNC1 (1:100; #WH0007134M1) antibodies
(Sigma-Aldrich Co., St. Louis, MO). Target protein expression was visualized using a Betazoid
3,3'-diaminobenzidine or a Warp Red chromogen kit (Biocare Medical, Concord, CA).
To quantify target protein expression in the FFPE sections, slides were scored
according to the staining intensity and percentage of MFAP5- and TNNC1- positive cells. To
quantify stromal MFAP5 expression, the expression scores were calculated by multiplying the
staining intensity (range, 0-3) by the percentage of stroma with MFAP5-positive staining.
Similarly, TNNC1 tumor expression scores were based on tumor TNNC1 staining intensity and
percentage tumor cells stained TNNC1-positive.
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6. CAF-derived MFAP5-stimulated motility of ovarian cancer cells
CAF793092 cells were seeded onto a 24-well plate at a density of 5 x 104 cells/ well.
The culture medium was then removed from the plate, and cells were washed with phosphatebuffered saline (PBS) the next day. Serum-free M105/199 media supplemented with 1 ng/ml
epidermal growth factor and 10 µg/ml of one of the following antibodies: 1) control IgG (EMD
Millipore Corp., Billerica, MA), 2) anti-MFAP5 antibody (#HPA010553; Sigma-Aldrich, St. Louis,
MO), 3) anti-αVβ3 antibody (#MAB1976Z; EMD Millipore Corp., Billerica, MA) and 4) anti-α5
antibody (#555615; BD Biosciences, San Jose, CA) was added to the wells. 72 hours later, 5 x
104 A224 or ALST cells were seeded onto each of the 8 µm porous cell culture inserts (BD
Biosciences, San Jose, MA) in the serum-free medium and co-cultured with CAFs preincubated with antibodies. After 15 hours of co-culture, cancer cells were stained with calcein
AM (Life Technologies Corp., Grand Island, NY). While non-migrated cancer cells in the cell
culture inserts were removed, the number of cancer cells migrated through the 8 µm pores
were quantified by obtaining images of the stained cells from nine random fields of view per
membrane using fluorescent microscopy and the Image-Pro Plus 7.0 software program (Media
Cybernetics Inc., Rockville, MD).

7. Recombinant MFAP5-increased ovarian cancer cell motility
OVCA432 cells were seeded onto chamber slides in 10% serum RPMI medium.
Attached cells were washed with PBS, followed by the addition of serum-free RPMI medium
with or without 500 ng/ml recombinant MFAP5 protein (recMFAP5). The cells were then placed
in an imaging chamber maintained at 37°C and supplemented with 5% CO2. Cell images were
taken every 15 minutes for 48 hours using confocal microscopy and the resulting series of
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images were analyzed by the MetaMorph Image Analysis software program (Molecular Devices
Inc., Sunnyvale, CA) to track the movement of individual cells.
To confirm exogenous MFAP5’s effects on ovarian cancer cell motility, motility assay
was performed using Boyden chambers with two additional ovarian cancer cell lines: A224 and
ALST. Serum-free RPMI medium with or without 50 ng/ml recMFAP5 was incubated with 10
µg/ml control IgG or anti-MFAP5, anti-αVβ3, or anti-α5 antibodies for 1 hour in the wells of 24well plates. After pre-incubation of medium, A224 or ALST cells (5 x 104) were then seeded
onto each 8 μm porous cell culture insert (BD Biosciences, San Jose, MA) with serum-free
medium and placed into the 24-well plate containing the pre-incubated cell culture medium and
incubated for 15 hours. At the end of the experiment, non-migrated cancer cells in the cell
culture inserts were removed and the number of cancer cells migrated through the 8 µm pores
were quantified by obtaining images of the stained cells from nine random fields of view per
membrane using fluorescent microscopy and the Image-Pro Plus 7.0 software program (Media
Cybernetics Inc., Rockville, MD)
To evaluate the role of calcium and TNNC1 in cell motility induced by MFAP5, ovarian
cancer cells were pretreated with the cell-permeant calcium chelator BAPTA/AM (B-6769; Life
Technologies Corp., Grand Island NY) at a concentration of 10 μM for 1 hour or transfected
with efficiency-evaluated TNNC1-specific siRNA (Silencer Select# s14271, s224742, s224743;
Life Technologies Corp., Grand Island NY) before performing the motility assay.

8. Recombinant MFAP5-increased microvascular endothelial cell motility
To evaluate the role of MFAP5 in angiogenesis, motility assay was performed using
Boyden chambers with two microvascular endothelial cell lines: hMEC-1 and TIME. Serum-free
MCDB131 and EBM-2 medium with or without 50 ng/mL recMFAP5 was incubated with 10
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µg/ml control IgG or anti-MFAP5, anti-αVβ3, or anti-α5 antibodies for 1 hour in the wells of 24well plates. 8 x 104 hMEC-1 or TIME cells were then seeded onto each 3 μm or 8 μm porous
cell culture insert respectively (BD Biosciences, San Jose, MA) with serum-free medium and
placed into the 24-well plate containing the pre-incubated cell culture medium. After a 4 hours
incubation period, endothelial cells were stained with calcein AM (Life Technologies Corp.,
Grand Island, NY). Non-migrated cancer cells in the cell culture inserts were removed and the
number of endothelial cells migrated through the pores were quantified by obtaining images of
the stained cells from nine random fields of view per membrane using fluorescent microscopy
and the Image-Pro Plus 7.0 software program (Media Cybernetics Inc., Rockville, MD)
To evaluate the role of calcium and LPP in cell motility induced by MFAP5,
microvascular endothelial cells were pretreated with the cell-permeant calcium chelator
BAPTA/AM (B-6769; Life Technologies Corp., Grand Island NY) at a concentration of 10 μM for
1 hour or transfected with efficiency-evaluated LPP-specific siRNA (Silencer Select #s8271,
s8269; Life Technologies Corp., Grand Island NY) before performing the motility assay.

9. MFAP5-stimulated ovarian cancer cell and microvascular endothelial cell invasion
The invasion potential of ovarian cancer cells and microvascular endothelial cells
treated with recMFAP5 were evaluated using a Matrigel invasion assay with BD BioCoat
Matrigel invasion chambers (BD Biosciences, San Jose, CA) according to the manufacturer’s
protocol. In brief, 3 x 104 A224 / ALST cancer cells or 5 x 104 hMEC-1 / TIME endothelial cells
were seeded onto an 8 µm porous BD BioCoat Matrigel invasion chamber in serum-free
medium and inserted into a BD Falcon TC companion plate with or without 200 ng/ml
recMFAP5. Ovarian cancer cells and microvascular endothelial cells were incubated at 37°C
for 15 hours and 4 hours respectively. After incubation, cells were then stained with calcein AM,
and non-invaded cells in the cell culture inserts were removed. The number of cancer and
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endothelial cells invaded through the Matrigel coated porous membrane were quantified by
obtaining images of the stained cells from nine random fields of view per membrane using
fluorescent microscopy and the Image-Pro Plus 7.0 software program (Media Cybernetics Inc.,
Rockville, MD).

10. Recombinant

MFAP5-induced

endothelial

barrier

disruption

and

increased

permeability of endothelial cell monolayer
1 x 104 hMEC1 or TIME cell were seeded onto each well of E-plate of the xCELLigence
system (Roche Applied Bioscience, Indianapolis, IN) and incubated at 37°C for 24 hours to
obtain confluent monolayer endothelial cell culture. On the next day, cell culture media in the
wells were replenished with serum-free MCDB131 or EBM-2 medium with or without 200ng/mL
recMFAP5. Electrical impedance generated by the monolayer endothelial cells sitting on gold
electrodes was measured throughout the course of the experiment by the real-time cell
analyzer (RTCA) as cell index (CI). Decrease in cell adhesion or monolayer integrity would be
indicated by a drop of CI value.
In vitro monolayer permeability assay was also performed to verify the observation by
the xCELLigence system. 20 mg/mL of FITC-dextran (relative molecular mass 70,000; SigmaAldrich Corp. St. Louis, MO) was added to the confluent hMEC-1 or TIME monolayers seeded
onto 0.4 μm pourous cell culture inserts in the presence or absence of 200 ng/mL recombinant
MFAP5. The appearance of fluorescence in the bottom wells of the Boyden Chambers were
monitored by analyzing 40 uL medium aliquots in a time course using a FLUO-star Omega
microplate reader (BMG Labtech Inc., Cary, NC). The passage of FITC-dextran through the
endothelial cell monolayer culture was used to assess the permeability and integrity of the
monolayer culture.
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11. Tube formation assay
100 μL of growth factor reduced BD Matrigel (BD Biosciences, San Jose, CA)
supplemented with 200 ng/mL recMFAP5, 500 ng/mL recMFAP5 or PBS was coated onto each
well of pre-chilled 24-well plate. The 24-well plate was then incubated at 37°C for 1 hour to
allow the Matrigel to solidify. After that, 5 x 104 hMEC-1 or TIME cells were resuspended in 1
mL of serum free MCDB131 or EBM-2 medium and seeded onto each well of the 24-well plate
coated with growth factor reduced BD Matrigel. The assay plate was then incubated at 37°C for
4 hours before the cells were stained with calcein AM (Life Technologies Corp., Grand Island,
NY). Endothelial tube formation was examined using a fluorescent microscope and the extent
of tube formation among different experimental groups was quantified and compared by using
the Angiogenesis module of the Leica MetaMorph Image Analysis software program (Molecular
Devices Inc., Sunnyvale, CA).

12. In vivo angiogenesis assay
In vivo angiogenesis assay was performed as previously described.106,107 500 μL of
Matrigel alone or Matrigel supplemented with one of the following: 1) 150 ng/mL basic fibroblast
growth factor (bFGF), 2) 200 ng/mL recMFAP5 or 3) 500 ng/mL recMFAP5 was injected
subcutaneously into nude mice. When warmed to body temperature, Matrigel polymerizes to
form subcutaneous plugs. After 5 days, the mice were sacrificed and Matrigel plugs were
excised, fixed in 10% formalin, embedded in paraffin and sectioned. Paraffin sections were
stained with anti-CD34 antibody (#GTX28158; GeneTex Inc., Irvine, CA). The extent of tube
formation among different experimental groups was quantified and compared using the
angiogenesis module of the MetaMorph Image Analysis software program (Molecular Devices
Inc., Sunnyvale, CA).
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13. Derivation of MFAP5-overexpressing NOFs
The telomerase-immortalized human NOF cell line NOF151-hTERT was transduced
with lentiviruses packaged with the human MFAP5 open reading frame (#EX-D0360-Lv105;
GeneCopoeia, Rockville, MD). Stably transduced cells were selected using complete medium
supplemented with 1 μg/ml puromycin for 5 days. MFAP5 overexpression in stably transduced
NOFs was validated by Western blot analysis, in which the cell lysate and conditioned medium
from the resultant NOF cell line NOF151-LvMFAP5 were compared with those from the mocktransduced control cell line. A proliferation assay was performed using the xCELLigence
system (Roche Applied Bioscience, Indianapolis, IN) to ensure that the NOF151-LvMFAP5 and
NOF151-hTERT cells had similar growth rates.

14. MFAP5 overexpressing fibroblast-stimulated ovarian cancer cell migration and
invasion in vivo
5 x 104 control NOF151 cells or MFAP5-overexpressing NOF151 (NOF151-LvMFAP5)
cells resuspended in one part of PBS was mixed with two parts of Matrigel. 500 μL of the
resultant cell suspension was injected into the intraperitoneal cavity of anesthetized nude mice
and was allowed to form a Matrigel plug attached to the peritoneal wall. On the next day, 1 x
106 A224 or OVCA432 cells were injected intraperitoneally into the Matrigel plug bearing mice.
Matrigel plugs were harvested from A224- and OVCA432-injected mice at 48 and 72 hours
post cancer cell injection respectively. The resected plugs were fixed in formalin and processed
for cancer cell migration, invasion and histological evaluation.
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15. Fibroblast-derived MFAP5 enhanced intratumoral microvessel formation and ovarian
tumor growth
2 x 106 of luciferase expressing A224 ovarian cancer cells were injected or co-injected
with 2 x 106 of either NOF151-LvMFAP5 or the mock transduced NOF151 cells in PBS into
each nude mouse subcutaneously. 10 mice were included in each of the control or treatment
groups. Five days after cell injection, tumor progression was monitored and quantified by
luciferase based imaging using the IVIS® -200 bioluminescence and fluorescence imaging
system. (Caliper Life Sciences, Inc., Hopkinton, MA). At day 12, all mice were sacrificed and
weighted. The tumor collected were fixed in formalin and processed for histological evaluation.

16. Stromal MFAP5 silencing reduced intratumoral microvessel formation and ovarian
tumor progression
2 x 106 luciferase expressing A224 ovarian cancer cells resuspended in one part of PBS
and two parts of Matrigel were injected intraperitoneally into nude mice. 10 mice were
randomized into each of the control and treatment groups. One week after cancer cell injection,
chitosan nanoparticles packaged with either 5 μg non-targeting scrambled siRNA, mouse
mfap5-targeting siRNA 68 or siRNA 69 were injected intraveneously into each mouse of the
corresponding group at the frequency of twice per week, for 5 weeks. Tumor progression was
monitored and quantified by luciferase based imaging using the IVIS® -200 bioluminescence
and fluorescence imaging system (Caliper Life Sciences, Inc., Hopkinton, MA). At the end of
the experiment, all animals were sacrificed and tumor tissues were harvested. Weights of
tumor tissues were recorded, followed by formalin fixation and paraffin tissue block preparation.
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17. Murine stromal Mfap5 silencing reduced ovarian tumor growth and metastasis in
vivo
Luciferase labeled OVCA432ip ovarian cancer cells were suspended in 50 µl of Hanks’
balanced salt solution and injected directly into the left ovary of anesthesized nude mice
through a 1.5 cm incision. One week after tumor cell injection, chitosan nanoparticles packaged
with Mfap5-targeting siRNA or non-targeting siRNA were injected intravenously into nude mice
twice a week for a total of 7 weeks. 6 weeks after initial injection, tumor progression of each
treatment group was quantified by luciferase based imaging using the IVIS® -200
bioluminescence and fluorescence imaging system (Caliper Life Sciences, Inc., Hopkinton,
MA). At week 8, animals were sacrificed and necropsy was performed. The number, weight,
and location of individual tumor nodules were recorded. Tumor tissues were fixed in formalin
and further processed for histological evaluation.

18. Transcriptome profiling to identify signaling mechanism underlying MFAP5’s effect
on ovarian cancer and microvascular endothelial cells
Total RNA were isolated from OVCA432 cells treated with PBS or 200 ng/ml recMFAP5
and mouse endothelial cells invaded into the recMFAP5 containing Matrigel plugs obtained
from the in vivo angiogenesis assay. 100 ng of total RNA from each group were used to
generate biotin-labeled RNA using the MessageAmp Premier RNA amplification kit (Life
Technologies Corp., Grand Island NY) according to the manufacturer’s protocol. Biotin-labeled
RNA samples from human cancer cells and mouse endothelial cells were then subjected to
whole-genome transcriptome profiling using the GeneChip Human Genome U133 Plus 2.0
microarrays and the Genechip mouse genome 430 2.0 array (Affymetrix Inc., Santa Clara, CA)
respectively. Differentially expressed genes with expression levels at least 1.5-fold higher than
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those of the corresponding controls (p<0.05) were selected for further analyses using the
Ingenuity Pathway Analysis software program (Qiagen, Valencia, CA).

19. MFAP5 stimulates calcium-dependent F-actin rearrangement
5 x 104 A224, ALST, hMEC-1 or TIME cells were seeded onto 8-well Lab-Tek chamber
slides (Thermo Fisher Scientific, Pittsburgh, PA) and serum fasted for 24 hours. After serum
starvation, ovarian cancer cells and microvascular endothelial cells were then treated with fresh
serum-free medium supplemented with or without 200 ng/ml recMFAP5. After a 24 hours and 4
hours incubation for cancer cells and endothelial cells respectively, cells were fixed with 3.7%
formaldehyde and stained with Alexa Fluor 594 phalloidin (Life Technologies Corp., Grand
Island, NY) according to the manufacturer’s instructions to visualize the F-actin cytoskeleton.
Fluorescent microscopy was used to evaluate the MFAP5-induced F-actin cytoskeleton
rearrangement in cells.
To evaluate the role of calcium in MFAP5-induced F-actin cytoskeleton rearrangement,
ovarian cancer cells and microvascular endothelial cells were pretreated with the cell-permeant
calcium chelator BAPTA/AM (B-6769; Life Technologies Corp., Grand Island, NY) for 1 hour
before MFAP5 treatment and staining with Alexa Fluor 594 phalloidin. To study the effect of
TNNC1 and LPP in F-actin reorganization induced by MFAP5, ovarian cancer cells and
microvascular endothelial cells were transfected with TNNC1-specific and LPP-specific siRNA,
respectively, before MFAP5 treatment and staining with Alexa Fluor 594-phalloidin.

20. Protein fractionation and Western blot analysis of TNNC1 expression in TNNC1
siRNA-transfected cell lines
Knockdown of TNNC1 protein expression in A224 and ALST cells by siRNA transfection
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was confirmed by Western blot analysis. Prior to this analysis, cell pellets were collected from
non-targeting scrambled siRNA and TNNC1-targeting siRNA-transfected A224 and ALST cells.
Cytoplasmic protein fractions of the protein samples were obtained using the NE-PER nuclear
and cytoplasmic extraction reagents (Thermo Fisher Scientific Inc., Waltham, MA) according to
the manufacturer’s protocol. A polyclonal rabbit anti-human TNNC1 antibody (13504-1-AP;
Proteintech, Chicago, IL) was used to determine TNNC1 expression levels in the cytoplasmic
protein factions by Western blot analysis.

21. Traction force microscopy
The cell traction force exerted on a flexible substrate impregnated with fluorescent
microspheres by A224, ALST or hMEC-1 cells was determined according to measured
substrate displacements using the LIBTRC analysis library developed by Dr. Micah Dembo of
Boston University.108-110 In brief, polyacrylamide gel (5% acrylamide and 0.1% Bis-acrylamide,
thickness = 75 µm; Young’s modulus = 28 kN/m2) was prepared on glass coverslips with
fluorescent microspheres (0.2 μm diameter, yellow-green FluoSpheres; Life Technologies)
impregnated under the surface. The surface was then coated with 0.2 mg/ml collagen type I
(BD Biosciences, San Jose, CA) after photoactivation of the surface molecular linker
sulfosuccinimidyl-6-(4'-azido-2'-nitrophenylamino) hexanoate (sulfo-SANPAH; Pierce Chemical,
Dallas, TX). Cells were then seeded and cultured overnight on the prepared substrate. To
evaluate the effect of exogenous MFAP5 on the traction force exerted by cancer cells on the
substratum, cancer cells were treated with exogenous recMFAP5 and a series of images of
individual cancer cells were captured during the course of the experiment. A background image
of the fluorescent beads was also taken after the cells were removed from the substrate. The
LIBTRC library was then used to track the displacement of microspheres and compute the cell
traction force. All mages were collected using a TCS SP5 confocal microscope (Leica
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Microsystems, Buffalo Grove, IL).

22. [Ca2+]i measurement
A224, ALST or hMEC-1 cells that grew on collagen-coated Petri dishes with glass
bottoms were loaded with Fluo-4 AM in Hank’s balanced salt solution for 30 minutes followed
by 20 minutes to de-esterify the dye. Fluo-4 AM was excited at 488 nm, and its emission was
collected using a bandpass filter at 522/35 nm. Fluorescent images of the cells were collected
using a Leica TCS SP5 confocal microscope at 0.25 Hz. Calcium mobilization in cells was
quantified by measuring Fluo-4 AM fluorescent signal.

23. Immunoflourescence labeling of LPP and focal adhesion markers
5 x 104 hMEC-1 or TIME cells were seeded onto 8-well Lab-Tek chamber slides
(Thermo Fisher Scientific, Pittsburgh, PA) and serum fasted for 24 hours. After serum
starvation, cells were treated with fresh serum-free medium supplemented with or without 200
ng/ml recMFAP5 for 24 hours. After incubation, cells were fixed with 3.7% formaldehyde and
stained with an anti-LPP antibody (1:100; Cell Signaling Technology Inc., Beverly, MA) or an
anti-Vinculin antibody (1:100; Life Technologies Corp., Grand Island, NY) at room temperature
for 2 hours followed by a 1-hour incubation with the Alexa Fluor-488 Goat Anti-mouse IgG
antibody (1:1000; Life Technologies Corp., Grand Island, NY). Slides were then mounted using
the ProLong Diamond Antifade Mountant (#P36961, Life Technologies Corp., Grand Island,
NY) and fluorescent microscopy was performed to evaluate the expression level and
localization of LPP and Vinculin in endothelial cells.
To determine whether MFAP5-induced LPP expression localized at the focal adhesion
complexes of endothelial cells, immunolocalization of LPP and one of the following focal
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adhesion markers: 1) Vinculin, 2) Paxillin and 3) FAK, was performed by sequential
immunostaining using an anti-LPP antibody (1:100; Cell Signaling Technology Inc., Beverly,
MA) followed by staining with anti-Vinculin antibody (1: 100; #700062; Life Technologies Corp.,
Grand Island, NY), anti-Paxillin antibody (1:50; #AF4259; R&D Systems Inc., Minneapolis, MN)
or anti-FAK antibody (1:100; #3285; Life Technologies Corp., Grand Island, NY).
To evaluate the role of LPP in focal adhesion formation induced by MFAP5,
microvascular endothelial cells were transfected with LPP-specific siRNA, before MFAP5
treatment and staining with anti-LPP antibody and anti-Vinculin antibody.

24. Monoclonal anti-mfap5 antibody attenuated ovarian cancer cell and microvascular
endothelial cell motility
Immortalized normal ovarian fibroblasts,

NOF151, or MFAP5 overexpressing

fibroblasts, NOF151 LvMFAP5, were seeded onto each well of a 24-well plate (1 x 105 cells
/well) in serum-free medium and incubated at 37ºC for 3 days. After that, fibroblasts were
incubated with10 µg/mL of control mouse IgG, anti-MFAP5 monoclonal antibody clone 64A or
clone 117B for 1 hour. After incubation, 5 x 104 hMEC-1 or TIME endothelial cells were seeded
onto each 8 μm porous cell culture insert (BD Biosciences, San Jose, MA) in serum-free
medium and incubated with the control fibroblasts or MFAP5-overexpressing fibroblasts in the
presence of IgG or anti-MFAP5 antibody for 4 hours. Similarly, 5 x 104 A224 or ALST ovarian
cancer cells in 8 μm porous cell culture inserts were incubated with fibroblasts for 15 hours. To
visualize cell migration, endothelial and cancer cells were stained with calcein AM (Life
Technologies Corp., Grand Island, NY). Non-migrated cells in the cell culture inserts were
removed and the number of cells migrated through the porous cell culture membrane were
quantified by obtaining images of the stained cells from nine random fields of view per
membrane using fluorescent microscopy and the Image-Pro Plus 7.0 software program (Media
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Cybernetics Inc., Rockville, MD).
To evaluate the inhibitory effect of anti-mfap5 antibody clone 130A on mouse
endothelial cell motility, motility assay was performed using Boyden chambers with a SV40transformed mouse endothelial cell line: SVEC4-10 (ATCC; #CRL-2181). Serum-free medium
with or without 100ng/mL recombinant mouse mfap5 was pre-incubated with 10 µg/ml control
IgG or anti-mfap5 antibody clone 130A for 1 hour in the wells of a 24-well plates. After antibody
pre-incubation, 8 μm porous cell culture inserts (BD Biosciences, San Jose, MA) were placed in
each of the wells and 5 x 104 SVEC4-10 cells were seeded onto the cell culture inserts in
serum-free medium and incubated for 4 hours. To visualize cell migration, endothelial and
cancer cells were stained with calcein AM (Life Technologies Corp., Grand Island, NY). Nonmigrated cells in the cell culture inserts were removed and the number of cells migrated
through the porous cell culture membrane were quantified by obtaining images of the stained
cells from nine random fields of view per membrane using fluorescent microscopy and the
Image-Pro Plus 7.0 software program (Media Cybernetics Inc., Rockville, MD).

25. Clone 130A anti-mfap5 antibody suppressed ovarian tumor growth in vivo
To study the inhibitory effects of anti-MFAP5 monoclonal antibodies on ovarian tumor
progression in vivo, 3 x 106 luciferase-labeled OVCA432 cells were I.P. injected into nude mice.
1 week after tumor cell injection, mice randomized into the treatment and control group (N=12
per group) were injected twice weekly with 15 mg/kg of anti-MFAP5 antibodies clone 130A and
15 mg/kg of control normal mouse IgG respectively for a total of 6 weeks. During the course of
the experiment, tumor progression was monitored by the IVIS® -200 bioluminescence and
fluorescence imaging system (Caliper Life Sciences, Inc., Hopkinton, MA).,100 µL of 10 mg/mL
FITC-dextran (relative molecular mass 200,000; Sigma-Aldrich Corp. St. Louis, MO) was
injected via tail vein into mice before the mice were sacrificed for the later evaluation of vessel
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leakiness. Tumor weight was recorded to evaluate tumor progression and 6 μm frozen tissue
sections were prepared from tumor tissues harvested using the Leica CM1850 cryostat (Leica
Microsystems, Buffalo Grove IL) for the evaluation of the effect of anti-mfap5 antibody on
intratumoral microvessel leakiness by fluorescent microscopy.

26. Anti-mfap5 antibody clone 130A increased paclitaxel bioavailability in ovarian tumor
tissues
10 nude mice were intraperitoneally injected with 3 x 106 luciferase-labeled OVCA432
cells. At 1 week after cancer cell injection, tumor bearing animals were I.P. injected with 15
mg/kg of control normal mouse IgG or anti-mfap5 antibody clone 130A twice weekly for a total
of 4 weeks. 1 mg/kg of Oregon Green 488-conjugated paclitaxel (Life Technologies Corp.,
Grand Island, NY) was I.V. injected into each of the animals at 1 hour before they were
sacrificed. Tumor weight was recorded and 6 μm frozen tissue sections were prepared from
tumor tissues harvested using the Leica CM1850 cryostat (Leica Microsystems, Buffalo Grove
IL) to evaluate the effects of anti-mfap5 antibody on the bioavailability of paclitaxel.

27. Toxicity test on anti-MFAP5 antibodies
Nude mice were treated with anti-MFAP5 antibody clones 64A, 117B or 130A for the
experimental groups and PBS for the control group (N=3 per group) twice weekly for 2 weeks.
Complete blood count (CBC) and chemistry panel were performed to measure the levels of 1)
albumin, 2) alkaline phosphatase (ALP), 3) alanine aminotransferase (ALT), 4) aspartate
aminotransferase (AST), 5) blood urea nitrogen (BUN), 6) creatinine, 7) globulin and 8) total
proteins in serum samples collected. In addition, H&E stained tissue sections were examined to
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evaluate and identify the possible organ or tissue toxicity due to treatment of anti-MFAP5
antibodies.

28. Statistical analysis
The SPSS 19 (IBM Corp., Armonk, NY) and Prism 5.0 (GraphPad Software, La Jolla,
CA) software programs were used to perform statistical tests. All in vitro experiments were
repeated independently in triplicate. A two-tailed Student t-test was used to determine
differences in sample means for data with normally distributed means. The Mann-Whitney U
test was used for analysis of nonparametric data. A p-value less than 0.05 was considered
statistically significant.

29. Accession numbers
Data files from the transcriptome profiling analysis were deposited in the Gene
Expression Omnibus (GEO; National Center for Biotechnology Information, Bethesda, MD).
Transcriptome profiling data for microdissected ovarian tissue samples was assigned the GEO
accession number GES40595, and microarray data for MFAP5-treated OVCA432 cells was
assigned the GEO accession number GES40643.
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Results
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Specific aim I: The role of CAF derived MFAP5 on ovarian cancer cell growth, motility
and invasion potential

This section is based upon Leung, C.S., Yeung, T.L., Yip, K.P., Pradeep, S., Balasubramanian,
L., Liu, J., Wong, K. K., Mangala, L.S., Armaiz-Pena, G. N., Lopez-Berestein, G., Sood, A.K.,
Birrer, M. J., Mok, S. C., Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect
of stromal MFAP5 on ovarian cancer metastatic potential. Nature communications 5, 5092
(2014). doi: 10.1038/ncomms6092, used with permission.
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A. Ovarian cancer associated fibroblasts express high levels of MFAP5
The stromal microenvironment is known to provide a niche that supports tumor growth.2
To identify mediators produced by the stromal microenvironment that support ovarian tumor
growth, transcriptome profiling was performed with RNA extracted from microdissected stromal
and epithelial components of ovarian tumor tissues, which included tumor epithelial
components (N=33), normal ovarian surface epithelial (OSE) cells (N=6), stromal CAFs (N=33)
and normal stromal fibroblasts (N=8). Microdissection was performed as previously described
(Fig. 12).111 Areas with immune cell and blood vessel infiltration were excluded to minimize
contamination. Among the differentially expressed genes, we identified 19 upregulated
secretory protein coding genes in the stromal component of HGSOC samples (Fig. 13 and
Table 1). Microfibrillar-associated protein 5 (MFAP5), which we have shown to be amplified and
overexpressed in a subset of ovarian cancer cells,75 was selected for further validation.
Validation by quantitative real-time PCR revealed significantly higher levels of MFAP5 mRNA
expression in the cancer stroma than the epithelial components and normal ovarian stroma
(Fig. 14). Immunohistochemisty also revealed higher level of MFAP5 protein expression in the
cancer-associated stroma, particularly in CAFs, than in ovarian cancer cells (Fig. 15). Western
blot analysis confirmed a higher endogenous level of MFAP5 in ovarian CAFs when compared
to normal fibroblasts and ovarian cancer cell lines (Fig. 16).
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Fig. 12: Microdissection of (A) normal ovarian tissue and (B) high-grade serous
ovarian tumor samples. After fixation, frozen tissue sections were stained with methyl
green to visualize the histologic features (left panels). Stromal and epithelial components in
both normal and cancerous tissue were dissected for RNA extraction. During dissection,
areas of interest were carefully outlined (middle panels). Areas with immune cell or blood
vessel infiltration were avoided to minimize contamination. The areas of interest were
recovered from the slides for further processing (right panels). (Yeung, T.L., et al. TGF-beta
modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor
microenvironment. Cancer research 73, 5016-5028 (2013), Supplementary figure 1)

B. Overexpression of stromal MFAP5 predicts poor patient survival
To determine the clinical significance of stromal MFAP5 expression, we performed
MFAP5 immunolocalization on 130 advanced HGSOC samples. Kaplan-Meier analysis and
log-rank test showed that high stromal MFAP5 expression is significantly associated with poor
clinical outcomes (p<0.001) (Fig. 17). Patients expressed high (above the median) and low (at
or below the median) stromal MFAP5 had a median overall survival duration of 24 months and
54 months respectively. Cox regression analysis with adjustment for age and debulking status
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confirmed the prognostic significance of stromal MFAP5 expression (hazard ratio, 2.603;
p=0.001).

Fig. 13: Differentially expressed genes in ovarian cancer-associated fibroblasts.
Heat map showing 819 significantly differentially expressed genes among microdissected
CAFs and ovarian epithelial tumor samples obtained from 33 patients, normal stromal
fibroblasts obtained from 8 normal ovaries, and 6 normal ovarian surface epithelial tissue
samples. 19 upregulated secretory protein-coding genes were identified in the CAFs
samples.
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Table 1: Secretory proteins unregulated in CAFs compared with HOSE, NOFs and
ovarian cancer epithelia.

Fig. 14: Validation of MFAP5 overexpression in ovarian cancer-associated
fibroblasts at mRNA level. Quantitative RT-PCR analysis of RNA isolated from
microdissected normal ovarian cortical fibroblasts, and the stromal fibroblastic (S: green
bars) and epithelial (T: red bars) components from the same patients are shown. Normal
fibroblasts did not have MFAP5 expression. Cancer stromal fibroblasts had significantly
higher levels of MFAP5 expression than did those in the epithelial components (p<0.001).
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Fig. 15: Immunolocalization of MFAP5 in advanced stage high-grade serous
ovarian tumor tissues. Representative images for high (A) and low (B) levels of
MFAP5 expression in the cancer stroma. S, Cancer stroma; T, epithelial component.
Bar = 100 μm.

Fig. 16: Validation of MFAP5 overexpression in ovarian cancer-associated
fibroblasts at protein level. Western blot analysis demonstrated higher levels of
MFAP5 expression in CAFs than in NOFs and ovarian cancer cells. Relative
normalized protein expression levels were presented.
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Fig. 17: Evaluation of clinical significance of MFAP5 overexpression.
Immunolocalization of MFAP5 was performed on 130 advanced HGSOC tissues samples to
determine the clinical relevance of stromal MFAP5 expression and HGSOC patient survival.
Kaplan-Meier analysis and log-rank test revealed that low stromal MFAP5 expression was
significantly associated with a longer overall survival duration than patients who have high
stromal MFAP5 expression (p<0.001). Patients with high (above the median) and low (at or
below the median) stromal MFAP5 expression levels had a median overall survival duration
of 24 months and 54 months respectively.

C. CAF-derived MFAP5 protein stimulates motility and invasiveness of ovarian cancer
cells
Previous studies by our group revealed that MFAP5 could exert its effect on cancer
cells in an autocrine manner via binding of its RGD domain to αVβ3 integrin. To determine CAFderived MFAP5’s role on ovarian cancer progression, CAFs expressing high levels of MFAP5
were co-cultured with A224 and ALST ovarian cancer cells which have undetectable levels of
endogenous MFAP5 and high levels of αVβ3 integrin expressions (Fig. 18). Experimental results
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demonstrated that anti-MFAP5 and anti-αVβ 3 integrin antibody attenuated the stimulatory effect
of MFAP5 on cancer cell motility (p<0.001) (Fig. 19).

Fig. 18: Immunocytochemical analysis on the differential expression of αVβ3 integrin
receptor in a panel of HGSOC cell lines. 3 αVβ3 integrin expressing ovarian cancer cell
lines: A224, ALST and OVCA432 were selected for the functional characterization of
MFAP5. Green: αVβ3 integrin; Red: nuclei.
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Fig. 19: Relative motility of ovarian cancer cells when co-cultured with CAF793092
primary ovarian CAFs in the presence of different antibodies. Control IgG, and anti-α5
antibodies did not affect cancer cell motility, while anti-αVβ3 and anti-MFAP5 antibodies
attenuated cancer cell motility in the co-culture system (mean ± SD of 3 independent
experiments; p<0.001).

Real-time imaging of HGSOC cell line OVCA432 treated with purified recombinant
MFAP5 protein (recMFAP5) revealed that exogenous recMFAP5 increased OVCA432 cell
motility (Fig. 20). To further validate the motility-stimulating effects of exogenous MFAP5,
Boyden chamber based motility assays were performed on A224 and ALST cell lines.
Increased number of migrated cancer cells was observed in both recMFAP5-treated cell lines.
Presence of anti-αVβ3 antibody attenuated the stimulatory effect of MFAP5 on cell motility
(p<0.01) (Fig. 21). Data from the co-culture studies and exogenous MFAP5 treatment
confirmed that the stimulatory effect of MFAP5 on ovarian cancer cell motility is mediated by its
binding to the αVβ3 integrin receptor.
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Fig. 20: Exogenous MFAP5 enhanced OVCA432 cell motility. A series of images
obtained from treatment of OVCA432 cells with recombinant MFAP5 protein in a
temperature controlled imaging chamber for 48 hours was analyzed using the MetaMorph
Image Analysis software program for tracking of the movement of individual cells.
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Fig. 21: Exogenous MFAP5 enhanced ovarian cancer cell motility in Boyden
chambers. Relative motility of cancer cells was evaluated after treatment with recombinant
MFAP5 in the presence of control IgG, anti-α5 or anti-αVβ3 antibodies compared with
antibody-free controls, the presence of anti-αVβ3 antibodies significantly abrogated MFAP5induced cell motility (mean ± SD of 3 independent experiments; p<0.01).

In addition, A224 and ALST cells seeded onto Matrigel matrix with recMFAP5 resulted
in three times the number of cells invaded through the matrix when compared to the control
(Fig. 22), suggesting that MFAP5 also stimulated invasion potential of ovarian cancer cells.
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Fig. 22: Exogenous MFAP5 enhanced ovarian cancer cell invasiveness. Invasion assay
using Matrigel invasion chamber showed that recombinant MFAP5 enhanced ovarian cancer
cell invasiveness (mean ± SD of 3 independent experiments; p <0.001).

D. CAF-derived MFAP5-stimulated motility and invasion potential of ovarian cancer
cells in vivo
To determine the effects of exogenous MFAP5 on ovarian tumor growth in vivo, a
MFAP5-overexpressing NOF cell line was created. Overexpression of MFAP5 was confirmed
by Western blot analysis (Fig. 23). Cell proliferation assay demonstrated similar proliferation
rates of MFAP5-overexpressing NOFs and mock-transduced control NOFs (Fig. 24). For the in
vivo study, fibroblasts embedded Matrigel plugs were I.P. implanted into nude mice followed by
cancer cell injection (Fig. 25A). Matrigel plugs harvested were double-stained for cytokeratin 18
and MFAP5. Results showed that more cancer cells were found in Matrigel plugs embedded
with MFAP5-overexpressing fibroblasts than those embedded with control fibroblasts (Figs.
25B and 25C), suggesting that stromal MFAP5 promoted ovarian cancer cell migration and
invasion into the Matrigel plugs.
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Fig. 23: Validation of MFAP5-overexpressing fibroblast line generated. Overexpression
and secretion of MFAP5 were validated by Western blot detection of the target protein in the
lysate and conditioned media for NOFs overexpressing MFAP5 (NOF151-LvMFAP5 cells).

Fig. 24: Growth rate of MFAP5-overexpressing fibroblasts compared to parental
fibroblast line. Real time monitoring of cell proliferation rate showing that NOF151LvMFAP5 cells had a proliferation rate comparable with that of the corresponding control cell
line, NOF151 (mean ± SD of 3 independent experiments).
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E. In vivo stromal Mfap5 silencing reduced ovarian tumor growth and metastasis
To evaluate the effect of stromal MFAP5 silencing in ovarian cancer metastasis, we
silenced murine stromal Mfap5 in an orthotopic mouse model of ovarian carcinoma112,113 by
intravenous injection of Mfap5-targeting siRNAs incorporated chitosan nanoparticles (CH-NP)
(Fig. 26A). The efficacy of three siRNA sequences on murine Mfap5 silencing was evaluated in
mouse fibroblasts (Fig. 26B). Two Mfap5-targeting siRNAs and a non-targeting sequence were
packaged with CH-NP and delivered via tail vein to luciferase labeled cancer cells bearing nude
mice throughout the course of the experiment. Significantly lower luciferase activity was
detected in Mfap5 knockdown groups compared to the control group at week 6 (Fig. 26C). At
the end point of the study, necropsy revealed amelioration of cancer metastasis in the stromal
Mfap5 silenced groups when compared to the control group while the primary tumor burden
between groups had no significant difference (Figs. 26D and 26E). Mfap5 siRNAs/CH-NP
resulted in a significant decrease in the total number of tumor nodules (p<0.001), tumor weight
(p<0.001) and volume of ascites (p<0.001) (Fig. 26F), suggested that stromal Mfap5 silencing
inhibited ovarian tumor growth and metastatic spread. Immunostaining was performed on
paraffin sections of tumor tissue harvested to validate in vivo silencing of murine stromal Mfap5
(Fig. 26G).
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Fig. 25: Stromal MFAP5 stimulated motility and invasion of ovarian cancer cells in
vivo. (A) A schematic diagram showing the procedures of using intraperitoneally
implanted Matrigel plugs to evaluate the effects of MFAP5 on invasion potential of ovarian
cancer cells. (B and C) Immunolocalization of MFAP5 (red signal) and cytokeratin 18
(brown signal) on paraffin sections Matrigel plugs collected from the peritoneal cavities of
mice. The invaded cancer cells with cytokeratin 18 staining were quantified using the
Image-Pro Plus software program (mean± SD; N = 10 Matrigel plugs per treatment group
for each cell line; p=0.0002 and 0.0162 for OVCA432 and A224 cells respectively).
Staining for MFAP5 showed that MFAP5 positive cells were found only in Matrigel plugs
embedded with MFAP5 overexpressing fibroblasts, suggesting that stromal MFAP5
promoted ovarian cancer cell invasion into the plugs implanted.
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Fig. 26: In vivo stromal Mfap5 silencing reduced ovarian tumor growth and metastasis.
(A) A schematic diagram showing the procedures of using intraovarian tumor injection model
to evaluate the effects of MFAP5 on invasion and metastatic potential of ovarian cancer cells.
(B) Quantitative RT-PCR data revealing efficient knockdown of stromal Mfap5 expression in
murine fibroblasts by Mfap5-specific siRNAs (mean ± SD of 3 independent experiments). (C)
Luciferase labeled ovarian cancer cells were injected into left ovary of nude mice and
luminescence was measured at week 6. Luciferase activities were significantly weaker in
stromal Mfap5 silenced groups when compared to the control siRNA groups (N=9-10 per
treatment group). (D) Reduced metastatic spread of cancer cells within the abdominal cavity
was observed in the Mfap5 siRNA encapsulated chitosan nanoparticles treated groups when
compared to the control group. (E) Primary tumor burden was quantified by measuring the
primary tumor area in the ovaries using images of haematoxylin and eosine tissue sections
prepared from tumors harvested from the control scramble siRNA treatment groups and two
Mfap5-targeting siRNA treatment groups. Similar primary tumor burdens were observed in the
control and Mfap5-targeted animal groups based on Mann–Whitney U-tests. (F) Significantly
reduced number of tumor nodules, tumor weight and ascites volume were observed in the
Mfap5 knockdown groups when compared with the control siRNA group after necropsy (mean
± SD; n=9-10 per treatment group; p<0.001). (G) Tumor tissues were fixed in formalin and
embedded with paraffin followed by immunolocalization of Mfap5 to confirm the successful
knockdown of stromal Mfap5 expression. S, Stroma; T, Tumor; Bar=100 μm.

F. Transcriptome profiling identified calcium-dependent signaling pathway activation
and troponin C type 1 upregulation in MFAP5-treated ovarian cancer cells
Transcriptome profiling on recMFAP5-treated and untreated OVCA432 cells followed by
pathway analysis identified a set of up-regulated motility-promoting genes associated with
calcium signaling in recMFAP5-treated cells (Figs. 27 and 28). Among them, troponin C type 1
(TNNC1) was chosen for further studies. TNNC1 contains a calcium-binding subunit and
facilitates the interaction between actin and myosin in skeletal and cardiac muscle cells and the
formation of stress fibers, suggesting that it may play a key role in mediating MFAP5’s
stimulatory effect on ovarian cancer cell motility. We performed quantitative RT-PCR analysis
on five MFAP5-treated ovarian cancer cell lines and observed a significant increase of TNNC1
expression in all of them (Fig. 29). Results from motility assays revealed that silencing of
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TNNC1 by TNNC1-targeting siRNA abolished MFAP5’s stimulatory effect on A224 and ALST
cell motility (Fig. 30), suggested that TNNC1 is the effector protein for MFAP5-enhanced
cancer cell motility. In addition, F-actin staining showed that recMFAP5 treatment led to an
increased density and more organized F-actin cytoskeleton in ovarian cancer cells (Fig. 31),
while these effects were abrogated in TNNC1-targeting siRNAs transfected cells (Fig. 32)
suggested that MFAP5 stimulated cell motility through induction of TNNC1 expression and Factin cytoskeleton reorganization.

Fig. 27: Motility-promoting genes upregulated by MFAP5 in ovarian cancer cells.
Heat map showing motility-promoting genes associated with calcium signaling whose
expressions were upregulated in MFAP5-treated OVCA432 cells. Among them, TNNC1
was chosen for follow up evaluations.
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Fig. 28: Pathway analysis of genes upregulated by MFAP5. Interaction network of motility
promoting and calcium signaling related genes whose expressions were upregulated in
MFAP5-treated OVCA432 cells was identified using the Ingenuity Pathway Analysis software
program (Ingenuity Systems, Redwood City, California).
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Fig. 29: Validation of TNNC1 upregulation in recMFAP5-treated cancer cells by
quantitative RT-PCR. Upregulation of TNNC1 mRNA expression in five serous ovarian
cancer cell lines after MFAP5 treatment (mean ± SD of 3 independent experiments;
p<0.001).
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Fig. 30: Evaluation of the role of TNNC1 in MFAP5 induced ovarian cancer cell motility.
Abrogation of MFAP5’s stimulatory effect on ovarian cancer cell motility by knockdown of
TNNC1 expression using TNNC1-targeting siRNAs and a scrambled non-targeting siRNA as
control (mean ± SD of 3 independent experiments).

Fig. 31: Fluorescent labeling of F-actin in MFAP5-treated ovarian cancer cells. MFAP5induced F-actin rearrangement and activated stress fiber formation in A224 and ALST cells
was visualized by immunofluorescence. Red: F-actin; Blue: nuclei.
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Fig. 32: MFAP5 induced increase in density and rearrangement of F-Actin cytoskeleton
were abrogated by siRNA silencing of TNNC1 in A224 and ALST cells.
Immunofluorescence was used to visualize the actin cytoskeleton of ovarian cancer cells.
While MFAP5 treatment increased density and promoted rearrangement of actin cytoskeleton
in both cell lines, the effects of MFAP5 were abrogated by knockdown of TNNC1 using
siRNA. Red: F-actin; Yellow: nuclei.

G. MFAP5’s effects on motility is mediated via calcium mobilization and increased
traction force in ovarian cancer cells
Transcriptome profiling and pathway analysis data suggest that cytosolic calcium
mobilization is integral to MFAP5’s effect on ovarian cancer motility. The observations that
MFAP5’s motility stimulatory effect was attenuated and F-actin reorganizing effect was
abrogated in calcium chelator BAPTA/AM preloaded cancer cells (Fig. 33), suggested that
calcium signaling is involved in modulating MFAP5’s functions. Using calcium dye Fluo-4 AM
and confocal fluorescence microscopy, we observed that exogenous MFAP5 mobilized
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intracellular Ca2+ in A224 and ALST cells (Fig. 34). Further evaluation on the mechanisms
involved in calcium mobilization in ALST cells showed that treatment with the L-type Ca2+
channel blocker nifedipine attenuated but did not abolish MFAP5-induced calcium mobilization
(Fig. 35A). Besides, L-type calcium channel opener BAYK8644 triggered calcium mobilization
in ALST cells (Fig. 35B), suggesting that MFAP5 induced exogenous Ca2+ entry via the L-type
voltage-gated channel, although other channels may be involved. Also, treatment with the IP3
receptor inhibitor xestospongin C but not the ryanodine receptor blocker attenuated MFAP5induced calcium mobilization, suggesting that IP3-sensitive Ca2+ stores are mobilized by
MFAP5 (Figs. 35C and 35D). Because IP3-sensitive Ca2+ store depletion can trigger storeoperated Ca2+ entry (SOCE) and is a common entry pathway in nonexcitable cells, we
evaluated whether a transient receptor potential channel antagonist, SKF96365, could
abrogate SOCE activated by thapsigargin in ALST cells. The result confirmed that an
exogenous Ca2+ entry mechanism resembling store-operated calcium entry was present in
ALST cells (Fig. 35E).
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Fig. 33: Evaluation of the role of calcium signaling in MFAP5 induced ovarian cancer
cell motility. Stimulatory effect of MFAP5 on ovarian cancer cell motility was attenuated by
the cell-permeant calcium chelator BAPTA/AM but not by the solvent control DMSO (mean
± SD of 3 independent experiments).

Fig. 34: The mean normalized time course of Ca2+ mobilization in A224 and ALST
cells induced by MFAP5. Hank’s balanced salt solution with or without MFAP5 or was
added to the bath of cells at t= 0 followed by the monitor of Ca2+ mobilization (mean ± SEM
of 10 independent experiments for each treatment group).
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Fig. 35: Calcium influx in ovarian cancer cells induced by MFAP5 treatment in the
presence of different channel blockers. (A) Mean normalized time course of Ca2+
mobilization in ALST cells induced by recombinant MFAP5 (200 ng/ml) in the presence of
nifedipine (100 μM, 30 minutes of preincubation). (B) Mean normalized time course of Ca2+
mobilization in ALST cells induced by BAYK8644 (2.5 μM). (C) Mean normalized time course
of Ca2+ mobilization in ALST cells induced by recombinant MFAP5 (200 ng/ml) in the
presence of the IP3 receptor inhibitor xestospongin C (10 μM, 30 minutes of preincubation).
(D) Mean normalized time course of Ca2+ mobilization in ALST cells induced by recombinant
MFAP5 (200 ng/ml) in the presence of ryanodine (50μM, 30 minutes of preincubation). (E)
Activation of store-operated calcium entry by thapsigargin in ALST cells. ALST cells were
incubated with 20 μM thapsigargin in the absence of extracellular Ca2+ for 25 minutes.
Subsequent addition of 2 mM Ca2+ to the medium resulted in rapid extracellular Ca2+ entry,
which was inhibited by treatment with 50 μM SKF96365. Dotted lines, standard errors.

Since calcium mobilization has been linked to increased cell traction force and cell
motility,114,115 we therefore used traction force microscopy to evaluate MFAP5’s effects on
cancer cells’ traction force generation. RecMFAP5 exposure induced amplitude increase and
cell traction force redistribution in A224 and ALST cells (Figs. 36A and 36B), suggested that
directional traction force induction is the physical mechanism of MFAP5-enhanced motility and
invasion potential. Furthermore, TNNC1 silencing abrogated the amplitude increase of traction
force induced by MFAP5 (Fig. 37), suggested that TNNC1 is the key molecule involved in
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traction force induction by MFAP5.

Fig. 36: Traction force induction by MFAP5 in ovarian cancer cells. (A) Cell traction
force maps of A224 and ALST cells before and after exposure to MFAP5. (B) The
normalized total traction force exerted by A224 and ALST cells induced by MFAP5. (Mean ±
SEM of 10 independent experiments for each treatment group).
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Fig. 37: The effect of TNNC1 silencing on traction force generation in ovarian cancer
cells. Silencing of TNNC1 expression by siRNAs attenuated the increase in total traction
force exerted by ALST cells to the substratum in the presence of exogenous MFAP5 (mean
± SEM of 10 independent experiments for each treatment group).

H. TNNC1 upregulation by MFAP5 was mediated through the activation of calciumdependent FAK/CREB/TNNC1 signaling pathway
Western blot analysis of key signaling molecules implicated in calcium-dependent
pathways and TNNC1 transcriptional regulation demonstrated increases in p-FAK (Y861), pPLC-γ1 (Y783), p-PKCθ (T538), p-ERK1/2 (T202/Y204), p-CREB (S133), total Jun, and p-Jun
(S63, S73 and S243) expression in MFAP5-treated cancer cells (Figs. 38A and 38B). Based on
our results, we hypothesized that binding of MFAP5 to αVβ 3 integrin activates FAK. FAK
activation activates PLC-γ1 and PKCθ, which regulate Ca2+ influx. Ca2+ mobilization leads to
ERK1/2 phosphorylation and subsequent cAMP response element-binding protein (CREB)
activation. Translocation of activated CREB to the nucleus leads to c-Jun transcription via
binding of activated CREB to cAMP-response element (CRE) in the c-Jun promoter, which then
upregulates TNNC1 expression. Increased TNNC1 protein level thereby enhances stress fiber
formation and cell motility (Fig. 39).
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Fig. 38: Western blot analyses on proteins isolated from MFAP5-treated A224 and
ALST ovarian cancer cells. (A) Treatment of exogenous MFAP5 increased p-FAK (Y861),
p-PLC-γ1 (Y783), p-PKCθ (T538), p-ERK1/2 (T202/Y204), p-CREB (S133), total Jun, and
p-Jun (S63, S73 and S243) expressions in A224 ovarian cancer cells. (B)Treatment of
exogenous MFAP5 increased p-FAK (Y861), p-PLC-γ1 (Y783), p-PKCθ (T538), p-ERK1/2
(T202/Y204), p-CREB (S133), total Jun, and p-Jun (S63, S73 and S243) expressions in
ALST ovarian cancer cells. Relative normalized protein expression levels with respect to
the corresponding control were presented.
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Fig. 39: Molecular mechanism by which MFAP5 induces ovarian cancer cell motility
and invasion potential. A graphical summary of the molecular signaling events involved in
MFAP5-mediated ovarian cancer cell motility and invasiveness.
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To test the hypothesis, Western blot analyses were performed. Pretreatment with the
anti-αVβ 3 integrin antibody abrogated MFAP5-induced FAK and PLC-γ1 phosphorylation (Fig.
40) suggested that αVβ3 integrin is responsible for MFAP5-induced FAK and PLC-γ1
phosphorylation. Previous studies showed that PLC-γ1 phosphorylation is stimulated by both
αVβ 3 engagement and formation of FAK/αVβ 3 complex.116,117 We therefore treated cancer cells
with an FAK inhibitor to determine whether MFAP5-induced PLC-γ1 phosphorylation is FAKdependent. Results demonstrated that phosphorylation of p-PLC-γ1 was attenuated in inhibitor
pretreated cells (Fig. 41), suggested that MFAP5-induced pPLC-γ1 phosphorylation is FAKdependent.

Fig. 40: Western blots showing blockade of αVβ3 integrin attenuated MFAP5 stimulated
FAK and PLC-γ1 phosphorylation. Pretreatment of A224 and ALST ovarian cancer cells
with an anti-αVβ3 integrin antibody abrogated MFAP5’s effect on FAK and PLC-γ1
phosphorylation, whereas pretreatment with an anti-α5 antibody and IgG had no effect.
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Fig. 41: Western blots showing FAK inhibitor abrogated MFAP5 stimulated PLC-γ1
phosphorylation. Increased p-PLC-γ1 expression in MFAP5-treated A224 and ALST cells
was observed in the presence of solvent control DMSO but not in the presence of an FAK
inhibitor SU6656.

Next, we sought to determine whether Ca2+ mobilization in MFAP5-treated ovarian
cancer cells is dependent on p-FAK–mediated PLC-γ1 and PKCθ phosphorylation. Previous
studies demonstrated that p-FAK induces PKCθ phosphorylation by activating PLC-γ1.118
Activated PLC-γ1 increases the hydrolysis of intracellular phosphatidylinositol-4, 5-biphosphate
to form two products: IP3 and DAG. IP3 induces endogenous Ca2+ release from the
endoplasmic reticulum via IP3 receptors, whereas DAG induces PKCθ phosphorylation and
activation. Furthermore, p-PKCθ directly mobilizes Ca2+.119,120 To determine whether PKCθ
activation is mediated by p-FAK in MFAP5-treated cells, Western blot analysis of p-PKCθ was
performed. p-PKCθ level increased in MFAP5-treated cells only in the absence of the FAK
inhibitor (Figs. 42). To determine whether the Ca2+ mobilization observed in MFAP5-treated
cells was mediated via PKCθ activation, cells were treated with MFAP5 with or without a PKCθ
inhibitor. PKCθ inhibitor decreased but did not eliminate Ca2+ mobilization (Fig. 43A),
suggesting that Ca2+ mobilization is mediated only in part by PKCθ activation. To determine
whether PLC activation is involved in Ca2+ mobilization, we studied the effect of PLC inhibitor
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U73122 on Ca2+ mobilization in MFAP5-treated cells. PLC inhibition effectively suppressed
Ca2+ mobilization (Fig. 43B), suggesting that PLC activation is the major signaling event
involved in MFAP5-mediated Ca2+ mobilization. However, Western blot analysis revealed that
PLC inhibitor abolished phosphorylation of PKCθ and PKCθ inhibitor abolished phosphorylation
PLC-γ1 (Fig. 44), indicated that activation of PLC and PKC are interdependent and affect Ca2+
mobilization in MFAP5-treated cancer cells.

Fig. 42: Western blots showing FAK inhibitor abrogated MFAP5 stimulated PKCθ
phosphorylation. Increased p-PKCθ expression in MFAP5-treated A224 and ALST cells
was observed in the presence of solvent control DMSO but not in the presence of an FAK
inhibitor.
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Fig. 43: Effects of PKCθ and PLC inhibitors on calcium influx induced by
recombinant MFAP5. (A) Mean normalized time course of Ca2+ mobilization in ALST
cells induced by recombinant MFAP5 (200 ng/ml) in the presence of a PKCθ
pseudosubstrate inhibitor (10 μM, 30 minutes of preincubation). (B) Mean normalized time
course of Ca2+ mobilization in ALST cells induced by recombinant MFAP5 (200 ng/ml) in
the presence of the PLC inhibitor U73122 (10 μM, 30 minutes of preincubation). Red lines
indicate standard errors. (Mean ± SEM of 10 independent experiments).
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Fig. 44: Western blots showing the effects of PKCθ and PLC inhibitors on PLC-γ1 and
PKCθ phosphorylation respectively. The PLC inhibitor U71322 abolished upregulation of
p-PKCθ expression and the PKCθ inhibitor attenuated upregulation of p-PLC-γ1 expression
in MFAP5-treated A224 and ALST cells.

To determine whether MFAP5-induced Ca2+ mobilization activates FAK via a feedback
loop, we evaluated the effect of Ca2+ chelator BAPTA/AM on MFAP5-induced FAK
phosphorylation. MFAP5-induced FAK phosphorylation was abrogated in BAPTA/AM-loaded
cells, suggested that this phosphorylation is Ca2+-dependent (Fig. 45).
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Fig. 45: Western blots showing the effects of calcium chelation on FAK
phosphorylation. MFAP5-induced FAK phosphorylation was not observed in BAPTA/AMloaded A224 and ALST cells.

ERK1/2 and CREB phosphorylation induced by recMFAP5 was attenuated in cells
preloaded with Ca2+ chelator BAPTA/AM (Fig. 46), and in cells pretreated with PKCθ inhibitor,
and PLC inhibitor U73122 (Figs. 47), suggested that MFAP5-induced ERK and CREB
activation is calcium-dependent and mediated via αVβ3 integrin/FAK/PKCθ- and αVβ3
integrin/FAK/PLC-γ activation.
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Fig. 46: Western blots showing the effects of calcium chelation on ERK and CREB
phosphorylations. Phosphorylation of ERK1/2 and CREB after recMFAP5-based treatment
was attenuated in BAPTA/AM-loaded A224 and ALST cells.
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Fig. 47: Western blots showing the effects of PKCθ and PLC inhibitors on ERK
phosphorylation. Application of a PKCθ pseudosubstrate inhibitor or PLC inhibitor
(U73122) abrogated phosphorylation of ERK1/2 in MFAP5-treated A224 and ALST cells.

CREB is known to be activated by ERK.121 To determine whether MFAP5 activates
CREB through ERK, the effect of ERK1/2 inhibitor on MFAP5-induced CREB activation was
evaluated. Pretreatment of cancer cells with ERK1/2 inhibitor abolished upregulation of pCREB expression, suggesting that MFAP5 activates CREB through ERK (Fig. 48). CREB,
together with co-activators, contributes to target gene transcription in response to Ca2+ and via
binding to the CRE. Our data demonstrated upregulation of c-Jun, which contains a CRE in its
promoter, in MFAP5-treated cells. Also, promoter analysis revealed that the TNNC1 promoter
consisted of potential AP-1 binding sites (Fig. 49), suggested that transcriptional upregulation
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of TNNC1 expression is mediated by CREB-mediated c-Jun expression. To verify that, we
evaluated the effects of CBP/CREB interaction inhibitor and c-Jun inhibitor SP600125 on
MFAP5-treated cells. Results demonstrated that CBP/CREB interaction inhibitor attenuated the
upregulation of p-c-Jun (Fig. 50) while SP600125 abrogated the upregulation of TNNC1 (Fig.
51). MFAP5-induced TNNC1 mRNA expression was abrogated in BAPTA/AM, CBP/CREB
interaction inhibitor, and c-Jun inhibitor pretreated cells (Fig. 52). These data confirmed that the
increase of TNNC1 expression induced by MFAP5 is calcium-dependent and mediated via
upregulation of c-Jun by CREB activation.

Fig. 48: Western blots showing the effects of ERK1/2 inhibitor on CREB
phosphorylation. Pretreatment of ovarian cancer cells with the ERK1/2 inhibitor abolished
the upregulation of p-CREB expression in MFAP5-treated A224 and ALST cells.
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Fig. 49: Promoter analysis revealed multiple potential AP-1 binding sites in the TNNC1
promoter. The nucleotide sequence of the TNNC1 promoter from 1500 base pairs upstream
the transcription start site was analyzed using the Biobase ExPlain Analysis Platform
(Biobase Biological Databases, Wolfenbüttel, Germany). Five potential AP-1 binding sites
were identified. The AP-1 transcription factor is a dimeric protein composed of proteins from
the c-Jun and c-Fos families. The result suggested that MFAP5-induced TNNC1
upregulatioin may be regulated through upregulation of c-Jun expression and AP-1
transcription activation.
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Fig. 50: Western blots showing the effects of CBP/CREB interation inhibitor on c-Jun
and p-c-Jun expressions. Pretreatment with the CBP/CREB interaction inhibitor attenuated
the upregulation of total c-Jun and p-c-Jun expression induced by MFAP5 in A224 and ALST
cells.

Fig. 51: Western blots showing the effect of c-Jun inhibitor on MFAP5 induced TNNC1
overexpression. Pretreatment with the c-Jun inhibitor abrogated the upregulation of TNNC1
expression induced by exogenous MFAP5 in A224 and ALST cells.
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Fig. 52: TNNC1 expression in ovarian cancer cells after pretreatment with calcium
chelator and different inhibitors. Abrogation of MFAP5-induced increase in TNNC1 mRNA
expression in A224, ALST, and OVCA432 cells after pretreatment with cell-permeant calcium
chelator BAPTA/AM, a CBP/CREB inhibitor, or a c-Jun inhibitor (mean ± SD of 3
independent experiments).

To validate the activation of ERK signaling and upregulation of TNNC1 by MFAP5 in
vivo, immunostaining of p-ERK1/2 and TNNC1 was performed on paraffin-embedded sections
of Matrigel plugs from the previously described animal study. We observed higher p-ERK1/2
and TNNC1 expression in cancer cells in the Matrigel plugs embedded with MFAP5overexpressing fibroblasts than in control Matrigel plugs (Fig. 53).
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Fig. 53: Validation of pERK and TNNC1 overexpressions in MFAP5 overexpressing
fibroblasts embedded Matrigel plugs. Immunolocalization of p-ERK1/2 and TNNC1 in
paraffin tissue sections of Matrigel plugs collected from the peritoneal cavities of mice
demonstrating that the effects of stromal MFAP5 on cancer cell motility and invasion
potential were mediated by upregulation of p-ERK1/2 and TNNC1 expression.

I.

Correlation between tumor TNNC1 and stromal MFAP5 expression in human HGSOC
samples revealed the clinical relevance of TNNC1
The relationship between tumor TNNC1 and stromal MFAP5 expression in 107 HGSOC

tumor samples was evaluated by immunohistochemistry (Fig. 54) and a significant positive
correlation between tumor TNNC1 and stromal MFAP5 expression (r=0.515, p<0.001) was
observed (Fig. 55). Furthermore, Kaplan-Meier analysis and log-rank test revealed that low
tumor TNNC1 expression was significantly associated with an improved survival (p=0.018) (Fig.
56). Cox regression analysis adjusted for age and debulking status (hazard ratio: 1.705;
p=0.029) confirmed the prognostic significance of tumor TNNC1 expression.

92

Fig. 54: Correlation between stromal MFAP5 and TNNC1 expressions in ovarian tumor
samples. Immunolocalization of TNNC1 and MFAP5 in advanced-stage HGSOC tumor
sections revealing a positive correlation between high stromal MFAP5 and high tumor
TNNC1 expression. S, stroma; T, tumor. Bar=100 μm.
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Fig. 55: Spearman’s rank correlation analysis between stromal MFAP5 and tumor
TNNC1 expressions. Positive correlation between stromal MFAP5 expression and tumor
TNNC1 expression in HGSOC tissue samples was observed (N=107; r=0.515; p<0.001).
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Fig. 56: Kaplan-Meier analysis of the clinical significance of tumor TNNC1
expression with 107 FFPE tumor samples obtained from HGSOC patients. Low tumor
TNNC1 expression is significantly correlated to better overall survival of HGSOC patients
(N=107; p=0.018).
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Specific aim II: The pro-angiogenic roles of stromal MFAP5 in ovarian cancer
progression
A. Pro-angiogenic MFAP5 stimulates endothelial cell motility potential and permeability
Increased microvessel density has been shown to be a poor prognostic marker for
different types of tumors including ovarian cancer.10-13,112 Staining data showed that expression
of stromal MFAP5, which previously found to be significantly associated with poor patient
survival, is significantly associated with CD31+ microvessel density in HGSOC (Fig. 57).

Fig. 57: Spearman’s rank correlation analysis between stromal MFAP5 and CD31
positive vessel density in HGSOC patient samples. Positive correlation between
stromal MFAP5 expression and CD31 positive vessel density was observed in HGSOC
tissue samples (N=121; r=0.818; p<0.001).

We further evaluate the role of MFAP5 in angiogenesis by treating human
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microvascular endothelial cells (hMEC-1) and telomerase immortalized microvascular
endothelial (TIME) cells with exogenous MFAP5 protein. The results showed that while there
was no effect of MFAP5 on endothelial cell proliferation rates, there was a significant increase
of motility in cells treated with MFAP5, which was abrogated by the presence of anti-αVβ3
integrin antibody but not by the α5 antibody or control IgG (Fig. 58), suggested that αVβ3 integrin
mediated the effects of MFAP5 on endothelial cell motility. In addition, by Boyden Chamber
assay with porous cell culture inserts coated with Matrigel, we showed three folds increase in
the numbers of hMEC-1 and TIME cells invaded through the matrix in recMFAP5 treated wells
when compared to the control (Fig. 59), suggesting that MFAP5 also stimulated invasion
potential of microvascular endothelial cells.

Fig. 58: Attenuation of MFAP5-induced microvascular endothelial cell motility by the
presence of anti-αVβ3 antibodies. Relative motility of microvascular endothelial cells was
evaluated after treatment with recombinant MFAP5 in the presence of control IgG, anti-α5 or
anti-αVβ3 antibodies compared with antibody-free controls (mean ± SD of 3 independent
experiments; p<0.01).
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Fig. 59: Exogenous MFAP5 promoted microvascular endothelial cell invasiveness.
Invasion assay using Matrigel invasion chamber showed that recombinant MFAP5 protein
enhanced microvascular endothelial cell invasiveness (mean ± SD of 3 independent
experiments; p<0.001).

Furthermore, tube formation assay demonstrated enhanced tubular network formation
by hMEC-1 and TIME cells seeded on Matrigel containing recMFAP5 when compared to the
control Matrigel in a dose-dependent manner (Fig. 60). Further analysis using the
angiogenesis module of the Metamorph Imaging Analysis software program confirmed that
there were significantly increased in the total tube length, total tube area, number of segment
and number of branch point in TIME cells seeded onto MFAP5 containing Matrigel in a dosedependent manner when compared with those seeded onto PBS containing Matrigel (p<0.05)
(Fig. 61). These data further support the pro-angiogenic roles of MFAP5.
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Fig. 60: In vitro tube formation assay on MFAP5 treated microvascular endothelial
cells. Tube formation assay on hMEC-1 and TIME showing more extensive tubular
structure formation on Matrigel mixed with recMFAP5 in a dose dependent manner when
compared to control.
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Fig. 61: Quantitative analysis for in vitro tube formation assay. Quantitative analysis
using the Leica Metamorph Angiogenesis Module showed that there were significantly
increased in the total tube length, total tube area, number of segment and number of branch
point in TIME cells seeded onto MFAP5 containing Matrigel in a dose-dependent manner
compared with those seeded onto Matrigel reconstituted with PBS (p<0.05).

In addition, blood vessel leakiness in tumors has been shown to facilitate excessive
fluid loss from the vasculature to the interstitial space, which increases the interstitial pressure
and reduces blood flow. This will negatively affect the distribution of systemically administrated
drugs in solid tumor.122 To evaluate the effect of MFAP5 on endothelial cell monolayer
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permeability in vitro, hMEC-1 or TIME cells were seeded onto to the E-plate of the
xCELLigence system to obtain confluent monolayer cultures for the impedance measurement
by the RTCA analyzer in the presence or absence of MFAP5. The results showed that there
was a significant decrease in impedance in MFAP5-treated endothelial cell monolayer cultures
suggested that there was a disruption of the endothelial monolayer integrity by MFAP5
treatment (Fig. 62). To further validate such observation, we performed an in vitro permeability
assay by measuring the traversing of FITC-labeled dextran (relative molecular mass 70,000)
through the hMEC-1 and TIME monolayers growing on 0.4µm porous cell culture membrane in
the presence or absence of recombinant MFAP5 protein. The result showed that MFAP5
increased passage of the fluorescent-labeled dextran from the cell culture insert to the bottom
wells. (Fig. 63)
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Fig. 62: Permeability assay using the xCELLigence system. Impedance measurement by
the xCELLigence system in the presence of MFAP5 showed that there were significant
decreases in the impedance of hMEC-1 and TIME monolayers when compared to the
control, suggesting that there was a disruption of the endothelial cell monolayer integrity by
the presence of MFAP5.
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Fig. 63: Permeability assay using Boyden chambers. Treatment with recombinant
MFAP5 protein facilitated the passage of FITC-labeled dextran (relative molecular mass
70,000) through the hMEC-1 and TIME monolayer cultures growing on the 0.4µm porous cell
culture membrane to the bottom wells.

B. Stromal MFAP5 enhanced matured intratumoral microvessel formation
To evaluate the roles of MFAP5 in angiogenesis in vivo, A224 ovarian cancer cells were
co-injected subcutaneously with either MFAP5-overexpressing NOFs or control NOFs. The
results showed a significant increase in tumor size and weight as well as the number of CD34+
microvessels in the tumor tissue with high stromal MFAP5 expression level (Fig. 64),
suggesting that stromal MFAP5 facilitated tumor angiogenesis in vivo, which could
subsequently lead to increased tumor growth. In addition, immunostaining of pericyte marker,
NG2, was performed on paraffin sections of tumor tissue harvested. The result showed
significantly increased pericyte coverage in MFAP5-overexpressed tumors, suggested that
MFAP5 stimulates the formation of matured intratumoral microvessels (Fig. 65).
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Fig. 64: The effects of stromal MFAP5 on ovarian cancer cells growth in vivo. (A) Tumor
growth for each treatment groups was quantified. (B) Significant increased tumor growth was
observed when A224 cells were co-cultured with MFAP5 overexpressing fibroblasts in vivo
(p=0.003). Box represents the interquartile range of the records and the line across the box
indicates the median. Whiskers indicate the highest and lowest values among the records
that are no greater than 1.5 times the interquartile range. Outliers (indicated by numbered
circles) are cases with values between 1.5 and 3 times the interquartile range. (C)
Immunolocalization of MFAP5 and CD34. Arrows indicate microvessels. (D) MFAP5 and
CD34 staining on tissue sections were quantified (p<0.01). For scatter plots, upper and lower
bars indicate the interquartile range of the records, and the middle line indicates the median.
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Fig. 65: The effect of stromal MFAP5 on pericyte coverage on intratumoral
microvessels. Immunostaining of pericyte marker, NG2, on paraffin sections of tumor tissue
harvested showed significantly increased pericyte coverage in MFAP5 overexpressed
tumors, suggesting that MFAP5 stimulates the formation of matured intratumoral
microvessels. Quantification analysis was performed using the Image Pro PLUS 7.0
software. For scatter plots, upper and lower bars indicate the interquartile range of the
records, and the middle line indicates the median.

To further delineate the roles of MFAP5 in angiogenesis in vivo, the numbers of
microvessels infiltrating the Matrigel plugs reconstituted with different concentration of
recMFAP5 and implanted subcutaneously in nude mice were quantified. The results showed a
significant increase in the total tube length, total tube area, number of segments and number of
nodes of CD34+ microvesels in Matrigel reconstituted with recMFAP5 in a dose-dependent
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manner when compared to the control (Figs. 66 and 67). These data further support the
promoting effects of MFAP5 on tumor angiogenesis.

Fig. 66: Effects of MFAP5 on tube formation of endothelial cells was demonstrated by
in vivo angiogenesis assay. More extensive tubular network structures were observed in
Matrigel reconstituted with recMFAP5 in a dose dependent manner. bFGF, a known proangiogenic protein, was used a positive control.
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Fig. 67: Quantitative analysis for in vivo angiogenesis assay. The phenotypes of
microvessels infiltrating the Matrigel reconstituted with different concentration of MFAP5 and
implanted subcutaneously in nude mice were quantified using the angiogenesis modules of
the MetaMorph Image Analysis software program. The results showed a significant increase
in the total tube length, total tube area, number of segments and number of nodes in tubular
structures formed in the presence of MFAP5 recombinant protein compared to the control in
a dose dependent manner (p<0.05). For each boxplot, the box represents the interquartile
range of the records and the line across the box indicates the median. Whiskers indicate the
highest and lowest values among the records that are no greater than 1.5 times the
interquartile range. Outliers (indicated by numbered circles) are cases with values between
1.5 and 3 times the interquartile range. Extremes (indicated by numbered asterisks) are
cases with values more than 3 times the interquartile range.
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C. Silencing of MFAP5 reduces intratumoral microvessel density and inhibits ovarian
tumor progression
To evaluate the feasibility of targeting stromal MFAP5 as a therapeutic approach for
ovarian cancer, the effect of silencing stromal mfap5 expression in nude mice by injecting
chitosan nanoparticles packaged with mfap5-targeting siRNA was determined. The efficacy of
siRNA sequences on mfap5 silencing was first evaluated by knocking down the target gene in
mouse fibroblast (Fig. 26B). Three siRNA sequences were tested and two of them that showed
the highest efficiency together with a non-targeting scrambled sequence were incorporated into
chitosan nanoparticles and delivered twice a week via tail vein injection into A224 ovarian
cancer cells bearing nude mice. Three weeks after initial injection, tumor progression in each of
the treatment groups was quantified using the IVIS-200 bioluminescence and fluorescence
imaging system (Caliper Life Sciences, Inc., Hopkinton MA). Significant lower luciferase activity
was detected in mfap5 knockdown groups when compared to the control group (Fig. 68). At
week 6, the animals were sacrificed and tumor tissues were harvested and weighted.
Significantly lower tumor weights were observed in the mfap5 knockdown groups when
compared to the scrambled siRNA-treated group (p<0.001) (Fig. 69). Immunolocalization of
mfap5 and CD34 on the tumor paraffin tissue sections showed lower stromal mfap5 expression
and lower CD34+ microvessel density in mfap5 knockdown groups when compared to the
controls, confirming the successful knockdown of mfap5 and reduction of intratumoral
microvessels by mfap5-targeting siRNAs delivered by nanoparticles (Fig. 70). Immunostaining
of CD34+ microvessels on tumor paraffin tissue sections obtained from an intra-ovarian cancer
cell injection animal model also demonstrated a significant decrease in CD34+ intratumoral
vessel density in tumors from stromal mfap5 knockdown animals (Fig. 71).
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Fig. 68: Luminescence imaging of tumor volume in mice treated with control siRNA or
mfap5-targeting siRNAs encapsulated chitosan nanoparticles. Tumor volume of each
treatment group was quantified by the IVIS-200 bioluminescence and fluorescence imaging
system (Caliper Life Sciences, Inc., Hopkinton MA). Significant lower luciferase activity was
detected in mfap5 knockdown groups when compared to the control group (p<0.05). For
each boxplot, the box represents the interquartile range of the records and the line across
the box indicates the median. Whiskers indicate the highest and lowest values among the
records that are no greater than 1.5 times the interquartile range. Outlier (indicated by
numbered circle) is case with values between 1.5 and 3 times the interquartile range.
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Fig. 69: Tumor weight of mice injected with control siRNA or mfap5-targeting siRNAs
encapsulated chitosan nanoparticles. After 6 weeks of injection, the animals were
sacrificed and tumors were removed and weighted. Significantly lower tumor weights were
observed in the mfap5 knockdown groups when compared to the scrambled siRNA group
(p<0.001). For each boxplot, the box represents the interquartile range of the records and the
line across the box indicates the median. Whiskers indicate the highest and lowest values
among the records that are no greater than 1.5 times the interquartile range. Outlier
(indicated by numbered circle) is case with value between 1.5 and 3 times the interquartile
range.
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Fig. 70: Validation of stromal mfap5 silencing by mfap5-targeting siRNAs
encapsulated nanoparticles and evaluation of mfap5 knockdown on intratumoral
microvessel density. Immunolocalization for mfap5 and CD34 on the tumor paraffin tissue
sections were performed and quantified by the Image Pro-Plus 7.0 software. The results
showed lower stromal mfap5 expression and lower CD34+ microvessels density in mfap5
knockdown groups and confirmed the successful knockdown of mfap5 and reduction of
intratumoral microvessel density by the mfap5-targeting siRNAs delivered by nanoparticles
(p<0.001). On CD34 staining micrographs, arrows indicate microvessels. For scatter plots,
upper and lower bars indicate the interquartile range of the records, and the middle line
indicates the median.
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Fig. 71: The effect of stromal mfap5 silencing on intratumoral microvessel density in
an intraovarian cancer cell injection animal model. Immunostaining for stromal mfap5
and CD34+ microvessels was performed on tumor paraffin tissue sections and quantified by
Image Pro-Plus 7.0 software. The result demonstrated a significant decrease in CD34+
intratumoral vessel density in mfap5 silenced tumors (p<0.01). For scatter plots, upper and
lower bars indicate the interquartile range of the records, and the middle line indicates the
median.

D. MFAP5 induces endothelial cell stress fiber formation in a calcium-dependent
manner
Capillary endothelium permeability and endothelial cell motility have been shown to be
influenced by mechanical forces conveyed by the extracellular matrix,123-128 suggesting that
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increased traction force by MFAP5 may attribute to the increase in motility potential and
permeability of the endothelial cells. To determine whether traction force induction plays a role
in MFAP5 induced angiogenesis in ovarian cancer tissue, hMEC-1 cells were grown on a
collagen-I coated polyacrylamide substratum impregnated with fluorescent beads, and the
displacement of fluorescent beads in the presence or absence of recombinant MFAP5 were
tracked with the algorithm developed by Munevar and colleagues.129 The results showed that
exogenous recombinant MFAP5 protein significantly increased traction force in hMEC-1 cells
when compared with those treated with HBSS only (Fig. 72). In addition, we demonstrated that
MFAP5 treated endothelial cells showed a significant increase in stress fibers (Fig. 73) and
focal adhesion (Fig. 74) formation, suggesting that MFAP5 may increase cytoskeleton tension,
which subsequently lead to endothelial cell contraction and increase its cell motility.
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Fig. 72: Traction force induction by MFAP5 in microvascular endothelial cells. Traction
force maps showing distribution of traction forces (purple color denotes highest force) in
hMEC-1 cells treated with control HBSS (A) and recMFAP5 (B & C). Regression lines
(purple) showing a significant difference in regression coefficient between HBSS (D) and
MFAP5 (E) treated cells. P<0.005 based on F-ratio. HBSS or recMFAP5 was added at t=0.

114

Fig. 73: Fluorescent labeling of F-actin in MFAP5 treated microvascular endothelial
cells. Confocal microscopy showing increased stress fiber formation in endothelial cell lines
hMEC-1 and TIME treated with exogenous MFAP5 protein. Red: F-actin; Blue: nuclei.
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Fig. 74: Exogenous MFAP5 stimulated focal adhesion formation in microvascular
endothelial cells. By immunolocalization of focal adhesion marker, vinculin and confocal
microscopy, increased focal adhesion complex formation in recMFAP5-treated hMEC-1 and
TIME endothelial cells was demonstrated. Green: vinculin; Blue: nuclei.

Since calcium has been shown to induce spatially coordinated increases in traction
force during the movement of keratinocytes,114 we also evaluated whether the effect of MFAP5
on endothelial cell motility and permeability is Ca2+ dependent. The results showed that
MFAP5’s stimulatory effect on endothelial cell motility (Fig. 75) and stress fiber formation (Fig.
Fig. 76) was abrogated by pre-loading the cells with permeant calcium chelator, BAPTA/ AM,
suggesting that calcium signaling is involved in modulating MFAP5’s function. Using the
calcium dye Fluo-4 AM and confocal fluorescence microscopy, we observed that exogenous
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MFAP5 mobilized intracellular Ca2+ in hMEC-1 cells (Fig. 77A), which further demonstrated that
calcium signaling is involved in the stimulatory effect of MFAP5 on endothelial cells. The use of
IP3 receptor inhibitor Xestospongin C (XC) but not a ryanodine receptor blocker attenuated
MFAP5-induced calcium mobilization, suggesting that MFAP5 induces calcium release via the
IP3 receptor instead of the ryanodine receptor (Fig. 77B & 77C). Furthermore, activation of
SOCE by thapsigargin in hMEC-1 was inhibited by treatment with a transient receptor potential
channel antagonist, SFK96365, (Fig. 77D) suggesting that an exogenous Ca2+ entry
mechanism resembling SOCE was present in hMEC-1 cells.

Fig. 75: Evaluation of the roles of calcium signaling in MFAP5 induced microvascular
endothelial cell motility. Stimulatory effect of recMFAP5 on endothelial cells motility was
blocked by calcium chelator, BAPTA, but not by the control solvent, DMSO. Data represents
the mean ± SD of three independent experiments. (p<0.01)
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Fig. 76: Evaluation of the roles of calcium signaling in MFAP5 induced stress fiber
formation in microvascular endothelial cells. Confocal microscopy data showed that
stimulatory effect of recMFAP5 on endothelial cells stress fiber formation was blocked by
calcium chelator, BAPTA, but not by the control solvent, DMSO. Red: F-actin; Blue: nuclei.
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Fig. 77: Calcium influx induced by recombinant MFAP5 protein in the absence or
presence of channel blockers in microvascular endothelial cells. (A) Mean normalized
time course of Ca2+ mobilization in hMEC-1 cells induced by recombinant MFAP5 (200
ng/ml). (B) Mean normalized time course of Ca2+ mobilization in ALST cells induced by
recombinant MFAP5 (200 ng/ml) in the presence of the IP3 receptor inhibitor xestospongin C
(10 μM, 30 minutes of preincubation). (C) Mean normalized time course of Ca2+ mobilization
in hMEC-1 cells induced by recombinant MFAP5 (200 ng/ml) in the presence of ryanodine
(50μM, 30 minutes of preincubation). (D) Activation of store-operated calcium entry by
thapsigargin in hMEC-1 cells by incubating cells with 20 μM thapsigargin in the absence of
extracellular Ca2+ for 25 minutes. Subsequent addition of 2 mM Ca2+ to the medium resulted
in rapid extracellular Ca2+ entry, which was inhibited by treatment with 50 μM SKF96365.
Dotted lines, standard errors.
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E. MFAP5 induces LPP upregulation and increases focal adhesion assembly
To further delineate the underlying molecular mechanisms by which MFAP5 modulates
endothelial cell motility and monolayer permeability, transcriptome profiling and pathway
analyses were performed on RNA isolated from microvessels infiltrating the Matrigel I.P.
implanted in mice mentioned in Fig. 66. Focusing on genes that have been shown to be
associated with cell-cell, and cell-substrate cytoskeleton interactions, we identified LIM domain
containing preferred translocation partner in lipoma (LPP) as the most significant up-regulated
gene in microvessels infiltrated the Matrigel reconstituted with MFAP5 when compared to those
with PBS and in microvascular endothelial cells treated with exogenous MFAP5 protein when
compared to the control (Fig. 78). Endothelial cells treated with exogenous MFAP5 protein
showed a significant increase in LPP mRNA and protein levels when compared with those
treated with PBS (Fig. 79). Immunofluorescent microscopy confirmed increased LPP
expression particularly in the focal adhesions at cell periphery and co-localized with other focal
adhesion proteins when the endothelial cells were treated with exogenous recMFAP5
compared with the control (Figs. 80 and 81). Furthermore, transfecting LPP-targeting siRNAs
into MFAP5 treated endothelial cell lines hMEC-1 and TIME completely abrogated the effect of
MFAP5 on cell motility (Fig. 82), suggesting that LPP is the key downstream effector molecule
involved in MFAP5-modulated endothelial cell motility.
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Fig. 78: Heat map showing differential expressed genes in endothelial cells retrieved
from in vivo angiogenesis assay. Result showed that LPP is one of the significantly
overexpressed genes in endothelial cells invaded into recMFAP5 reconstituted Matrigel
compared to those invaded into control Matrigel retrieved from in vivo angiogenesis assay.
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Fig. 79: Validation of LPP upregulation induced by MFAP5. Upregulation of LPP in
MFAP5 treated endothelial cells was validated (A) at mRNA level by quantitative RT-PCR
and (B) at protein level by western blot.

Fig. 80: Immunolocalization of LPP in recMFAP5 treated microvascular endothelial
cells. Immunofluorescent microscopy showed increased LPP expression particularly at cell
periphery connecting to the actin cytoskeleton. Red: F-actin; Blue: nuclei.
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Fig. 81: Co-localization of LPP with focal adhesion proteins in microvascular
endothelial cells. Immunofluorescent microscopy demonstrated increased LPP expression
co-localized with other focal adhesion proteins when the endothelial cells were treated with
exogenous MFAP5. Red: focal adhesion proteins; Green: LPP; Blue: Nuclei.

123

Fig. 82: The effect of LPP silencing on MFAP5 stimulated microvascular endothelial
cell motility. Stimulatory effect of recMFAP5 on endothelial cells motility was blocked by
LPP targeting siRNAs but not by non-targeting scrambled siRNA. Data represents the mean
± SD of three independent experiments. (p<0.01)

To evaluate whether LPP modulates the effects of MFAP5 on tumor angiogenesis and
vessel permeability, tube formation assay was performed in the presence or the absence of
MFAP5 with microvascular endothelial cells transfected with LPP-targeting siRNAs or
scrambled non-targeting siRNA. Results showed that exogenous MFAP5 protein induced
increase in total tube length, total tube area, number of segments and number of branch points
were abrogated when cells were transfected with LPP-targeting siRNAs but not with the control
non-targeting siRNA (Figs. 83 and 84). Besides, silencing of LPP attenuated the stimulatory
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effect of MFAP5 on F-actin cytoskeleton reorganization (Figs. 85 and 86), focal adhesion
formation (Figs. 87 and 88) and monolayer permeability (Fig. 89). These data suggest that
MFAP5 up-regulates LPP, which leads to an increase in focal adhesion, stress fibers formation
and traction force in cells, and subsequently increases endothelial cell motility potential and
allows contractile forces to be set up to pull apart the inter-endothelial cell junctions and thus
increases permeability.
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Fig. 83: The effect of LPP silencing on tube formation in recMFAP5-treated
hMEC-1 cells. Exogenous MFAP5 protein induced significant increase in total tube
length, total tube area, number of segments and number of branch points in hMEC-1
cells. Such induction was abrogated in LPP-targeting siRNAs (si69, si71) transfected
cells but in control non-targeting siRNA (N2) transfected cells. Error bars: +/- 1SEM.
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Fig. 84: The effect of LPP silencing on tube formation in recMFAP5-treated TIME
cells. Exogenous MFAP5 protein induced significant increase in total tube length, total
tube area, number of segments and number of branch points in TIME cells. Such
induction was abrogated in LPP-targeting siRNAs (si69, si71) transfected cells but in
control non-targeting siRNA (N2) transfected cells. Error bars: +/- 1SEM.
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Fig. 85: The effect of LPP silencing on stress fiber formation in recMFAP5-treated
hMEC-1 cells. Stimulatory effect of MFAP5 on F-actin cytoskeleton reorganization was
attenuated by silencing of LPP by LPP-targeting siRNAs but not by the control nontargeting siRNA in hMEC-1 cells. Red: F-actin; Blue: nuclei.

Fig. 86: The effect of LPP silencing on stress fiber formation in recMFAP5-treated
TIME cells. Stimulatory effect of MFAP5 on F-actin cytoskeleton reorganization was
attenuated by silencing of LPP by LPP-targeting siRNAs but not by the control non-targeting
siRNA in TIME cells. Red: F-actin; Blue: nuclei.
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Fig. 87: The effect of LPP silencing on focal adhesion formation in recMFAP5-treated
hMEC-1 cells. Focal adhesion formation induced by exogenous MFAP5 in hMEC-1 cells
was abrogated by LPP silencing by LPP-targeting siRNAs but not by the control nontargeting siRNA. Green: LPP; Red: Vinculin; Blue: nuclei.

Fig. 88: The effect of LPP silencing on focal adhesion formation in recMFAP5-treated
TIME cells. Focal adhesion formation induced by exogenous MFAP5 in TIME cells was
abrogated by LPP silencing by LPP-targeting siRNAs but not by the control non-targeting
siRNA. Green: LPP; Red: Vinculin; Blue: nuclei.
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Fig. 89: The effect of LPP silencing on MFAP5-induced monolayer permeability in
microvascular endothelial cells. MFAP5 induced permeability of endothelial cell monolayer
was abolished by transfecting hMEC-1 and TIME cells with LPP specific siRNA compared to
control. (p<0.01)

F. Calcium-dependent FAK/ERK/LPP signaling pathway modulates MFAP5-induced
endothelial cell motility and permeability
MFAP5 contains an RGD motif that has been shown to mediate adhesion and
spreading of fetal bovine aortic smooth muscle cells, ear cartilage chondrocytes, arterial
endothelial cells, human skin fibroblasts and osteoblasts through the αVβ3 integrin.74 In addition,
our data using hMEC-1 and TIME also demonstrated that anti-αVβ3 integrin antibody could
abrogate MFAP5-mediated effects on endothelial cell motility (Fig. 58). These data suggest that
αVβ3 integrin is a major receptor for MFAP5 and MFAP5 may play a role in αVβ3 integrin130

mediated angiogenesis.130 In addition, Ca2+ mobilization has been shown to be involved in
integrin signaling and cell migration131-133 and our data showed that pre-loading microvascular
endothelial cells with cell permeant calcium chelator, BAPTA/ AM, abrogated the stimulatory
effect of MFAP5 on endothelial cell motility (Fig. 75). These suggest that calcium signaling is
involved in the effect of MFAP5 on endothelial cells. Lastly, our data indicated that LPP is a key
downstream effector molecule that may play a role in modulating the effect of MFAP5 on
endothelial cell motility and permeability, therefore we hypothesize that binding of MFAP5 to
αVβ3 integrin may activate calcium dependent signaling pathways, which transcriptionally upregulate LPP expression and subsequently increase motility and permeability in endothelial
cells.
To test these hypotheses, we first examined the promoter sequence of LPP. We
identified multiple AP1 bindings, suggesting that LPP may be regulated by c-Fos/c-Jun (Fig.
90). Then focusing on genes that have been implicated in mediating cell motility and calcium
signaling, we identified a significant increase in p-FAK(Y861), p-PLC-γ1 (Y783), p-PKCθ
(T538), p-ERK1/2 (T202/Y204), p-MLC2 (T18/S19), p-CREB (S133), cJun and p-cJun (S73)
expression in microvascular endothelial cells treated with MFAP5, which may lead to upregulation of LPP and subsequently increased cell motility and permeability (Fig. 91).
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Fig. 90: Transcription factor binding site analysis on LPP promoter sequence. Multiple
AP1 binding sites were identified with the 1500 base pairs upstream the LPP transcription
start site. Analysis result suggested that increased c-Fos/c-Jun expression may
transcriptionally upregulate LPP.
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Fig. 91: Western blot analyses on proteins isolated from MFAP5-treated hMEC-1 and
TIME cells. Western blot analyses identified a significant increase in p-FAK(Y861), p-PLCγ1 (Y783), p-PKCθ (T538), p-ERK1/2 (T202/Y204), p-MLC2(T18/S19), p-CREB (S133),
cJun and p-cJun (S73) expression in microvascular endothelial cells treated with MFAP5,
which may lead to up-regulation of LPP and subsequently increased cell motility and
permeability.

In vitro experiments demonstrated that FAK plays an essential role in multiple signaling
pathways that lead to angiogenesis.134-137 Src-mediated coupling of FAK to integrin αVβ5 has
been shown to be essential for VEGF signaling.138 In addition, recent studies showed that Ca2+
elevations increase the residency of FAK at focal adhesions by means of tyrosine
phosphorylation of FAK, which subsequently leads to increased activation of FAK effectors
involved in focal adhesion disassembly.139 Since our data showed that MFAP5 induced
microvascular endothelial cell motility activity was suppressed by pre-treated with an anti-αVβ3
integrin antibody, and MFAP5 up-regulated p-FAK (Tyr861) expression was suppressed by
pretreated cells with calcium chelator, BAPTA/ AM (Fig. 92), we hypothesize that MFAP5mediated response in endothelial cells requires the binding of MFAP5 to αVβ3 integrin, which
subsequently leads to the activation of FAK. Activation of FAK will activate PKCθ, which has
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been shown to be able to regulate Ca2+ influx.119 Ca2+ mobilization activates ERK1/2, and
subsequently leads to CREB activation, and translocation to the nucleus. Binding of activated
CREB to the CRE of c-Jun may transcriptionally up-regulate LPP, which contains multiple AP1
binding sites in the promoter sequence (Fig. 93).

Fig. 92: Western blots showing the effects calcium chelation on FAK phosphorylation
in microvascular endothelial cells. MFAP5-induced FAK phosphorylation was not
observed in BAPTA/AM-loaded hMEC-1 and TIME cells.
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Fig. 93: Diagram showing the proposed signaling pathways by which MFAP5 regulates
LPP expression and LPP increases cell permeability and motility in endothelial cells.

To evaluate whether MFAP5-induced FAK and PLCγ1 phosphorylation is mediated
through its binding to αVβ3 integrin, and the formation of FAK/ αVβ3 complex, hMEC-1 and TIME
were pretreated with an anti-αVβ3 integrin antibody (LM609), anti-α5 antibody or control IgG
before treating with recombinant MFAP5. Pre-treated cells with anti- αVβ3 integrin antibody but
not anti-α5 antibody or control IgG abrogated the effect of MFAP5 on FAK and PLCγ1
phosphorylation (Figs. 94 and 95).
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Fig. 94: Western blots showing blockade of αVβ3 integrin attenuated MFAP5 stimulated
FAK phosphorylation in microvascular endothelial cells. Pretreatment of hMEC-1 and
TIME cells with anti- αVβ3 integrin antibody but not anti-α5 antibody or control IgG abrogated
the effect of MFAP5 on FAK phosphorylation.

Fig. 95: Western blots showing blockade of αVβ3 integrin attenuated MFAP5 stimulated
PLC-γ1 phosphorylation in microvascular endothelial cells. Pretreatment of hMEC-1 and
TIME cells with anti- αVβ3 integrin antibody but not anti-α5 antibody or control IgG abrogated
the effect of MFAP5 on PLC-γ1 phosphorylation.

Next, we evaluated whether PKCθ stimulated by MFAP5 in microvascular endothelial cells
is mediated by FAK phosphorylation. Previous studies showed that p-FAK can activate PKCθ
phosphorylation by promoting (PLC)-γ1 activity.140 Activated (PLC)-γ1 can increase the
hydrolysis of intracellular PIP2 to form IP3 and DAG, which can subsequently activate
PKCθ.141,142 Furthermore, PKCθ has been shown to be able to mobilize Ca2+ directly.119 Since
we showed increased p-FAK, and p-PKCθ expression, and increased Ca2+ mobilization and
oscillation in hMEC-1 cells treated with recMFAP5, we hypothesize that increased Ca2+
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mobilization and oscillation observed in recMFAP5 treated hMEC-1 cells may be due to an
increase in the phosphorylation of PKCθ by p-FAK. To test this hypothesis, we first evaluated
whether PKCθ activation is mediated by p-FAK in MFAP5 treated microvascular endothelial
cells. Western blot analysis on PKCθ was performed on hMEC-1 and TIME cells treated with
MFAP5 in the presence or the absence of FAK inhibitors (PF573228, Sigma-Aldrich Corp. St.
Louis, MO). Results showed that increased p-PKCθ expression in MFAP5 treated
microvascular endothelial cells was not observed in the presence of FAK inhibitors (Fig. 96).

Fig. 96: Western blots showing FAK inhibitor abrogated MFAP5 stimulated PKCθ
phosphorylation in microvascular endothelial cells. Increased p-PKCθ expression
occurred only in the absence of a FAK inhibitor in MFAP5-treated endothelial cells but not in
DMSO-treated control cells.

Since previous studies showed that PLC-γ1 phosphorylation can not only be stimulated
by αVβ3 engagement alone
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but also by the formation of FAK/ αVβ3 complex.117 FAK inhibitor

was therefore employed to investigate whether PLC-γ1 phosphorylation is also FAK
dependent. Our result showed that pre-treatment of hMEC-1 and TIME cells with FAK inhibitor
followed by treatment of recMFAP5 in the presence of the inhibitor attenuated the
phosphorylation of p-PLC-γ1 (Y783) (Fig. 97). This suggested that MFAP5 induced pPLC-γ1
(Y783) phosphorylation was FAK dependent. Besides, MFAP5-induced PKCθ phosphorylation
was attenuated in hMEC-1 and TIME cells treated with PLC inhibitor (U73122; #sc-3574) (Fig.
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98). This suggested that PKCθ activation is regulated by PLCγ1 phosphorylation. However, as
described in the MFAP5 stimulated signaling in ovarian cancer cells in Aim 1, PKCθ inhibitor
also abolished p-PLC-γ1 up-regulation indicating that the two pathways are inter-dependent
and both affect the Ca2+ mobilization in MFAP5 treated microvascular endothelial cells (Fig.
99).

Fig. 97: Western blots showing FAK inhibitor abrogated MFAP5 stimulated PLC-γ1
phosphorylation in microvascular endothelial cells. Increased p-PLC-γ1 expression
occurred only in the absence of an FAK inhibitor PF573228 in MFAP5-treated endothelial
cells but not in DMSO-treated control cells.

Fig. 98: Western blots showing PLC inhibitor abrogated MFAP5 stimulated PKCθ
phosphorylation in microvascular endothelial cells. The PLC inhibitor U71322 abolished
the upregulation of p-PKCθ expression in MFAP5-treated endothelial cells.
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Fig. 99: Western blots showing PKC inhibitor abrogated MFAP5 stimulated PLC-γ1
phosphorylation in microvascular endothelial cells. Pretreatment of hMEC-1 and TIME
cells with the PKC inhibitor abolished the upregulation of p-PLC-γ1 expression in MFAP5treated cells.

To investigate whether activation of ERK1/2 and CREB induced by MFAP5 is Ca2+
dependent and is mediated through activation of αVβ3 integrin/FAK/PKCθ, hMEC-1 and TIME
cells were treated with MFAP5 in the presence or the absence of BAPTA/AM and PKCθ
pseudosubstrate inhibitor. The results show that phosphorylation of ERK1/2 and CREB after
recMFAP5 treatment was attenuated in BAPTA/ AM loaded cells as shown by western blot
analyses (Figs. 100 and 101). These data suggest that both MFAP5 induced ERK and CREB
activation is calcium dependent. Besides, application of PKCθ pseudosubstrate inhibitor
abrogated phosphorylation of ERK1/2 (Fig. 102). These data suggest that MFAP5 induced
ERK1/2 activation is αVβ3 integrin/FAK/PKCθ dependent.
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Fig. 100: Western blots showing the effects of calcium chelation on ERK
phosphorylation in microvascular endothelial cells. MFAP5-induced Erk1/2
phosphorylation was not observed in BAPTA/AM-loaded hMEC-1 and TIME cells.

Fig. 101: Western blots showing the effects of calcium chelation on CREB
phosphorylation in microvascular endothelial cells. MFAP5-induced CREB
phosphorylation was not observed in BAPTA/AM-loaded hMEC-1 and TIME cells.
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Fig. 102: Western blots showing PKC inhibitor abrogated MFAP5 stimulated ERK1/2
phosphorylation in microvascular endothelial cells. Pretreatment of hMEC-1 and TIME
cells with the PKC inhibitor abolished the upregulation of p-Erk1/2 expression in MFAP5treated cells.

Since ERK dependent MLC2 and CREB activation has been reported,143,144 therefore,
we evaluated whether MLC2 and CREB activation is mediated through calcium dependent
ERK1/2 phosphorylation. The results showed that MFAP5 stimulated MLC2 and CREB
phosphorylation were attenuated by treating hMEC-1 and TIME cells with recMFAP5 in the
presence or the absence of ERK1/2 inhibitors (FR180204, Merck, Germany) (Figs. 103 and
104). This demonstrated that MFAP5 induced MLC2 and CREB activation via ERK1/2.

Fig. 103: Western blots showing ERK inhibitor abrogated MFAP5 stimulated MLC2
phosphorylation in microvascular endothelial cells. Pretreatment of hMEC-1 and TIME
cells with an ERK1/2 inhibitor abolished the upregulation of p-MLC2 expression in MFAP5treated cells.
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Fig. 104: Western blots showing ERK inhibitor abrogated MFAP5 stimulated CREB
phosphorylation in microvascular endothelial cells. Pretreatment of hMEC-1 and TIME
cells with an ERK1/2 inhibitor abolished the upregulation of p-CREB expression in MFAP5treated cells.

Finally, our data demonstrated up-regulation of c-Jun, which contains a CRE in its
promoter, in MFAP5-treated cells. Also, promoter analysis revealed that the LPP promoter
consisted of multiple potential AP-1 binding sites (Fig. 90), suggested that transcriptional upregulation of LPP expression may be controlled by CREB-mediated c-Jun expression. To test
this hypothesis, we evaluated the effects of CBP/CREB interaction inhibitor and c-Jun inhibitor
SP600125 on MFAP5-treated cells. Results demonstrated that CBP/CREB interaction inhibitor
attenuated the up-regulation of both c-Jun and p-c-Jun while SP600125 abrogated the upregulation of LPP (Figs. 105 and 106). These data confirmed that the increase of LPP
expression induced by MFAP5 is calcium-dependent and mediated via up-regulation of c-Jun
by CREB activation.
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Fig. 105: Western blots showing CBP/CREB interaction inhibitor abrogated MFAP5
stimulated c-Jun and p-c-Jun expression in microvascular endothelial cells.
Pretreatment with CBP/CREB interaction inhibitor attenuated the upregulation of total c-Jun
and p-c-Jun (S73) expression induced by MFAP5 in hMEC-1 and TIME cells.

Fig. 106: Western blots showing the effect of c-Jun inhibitor on MFAP5 induced LPP
overexpression in microvascular endothelial cells. MFAP5-induced LPP upregulation
was abrogated in c-Jun inhibitor, SP600125, treated hMEC-1 and TIME cells.

After demonstrating that MFAP5 can up-regulate LPP through the activation of
FAK/ERK/CREB signaling network, we determined whether LPP can modulate the effect of
MFAP5 on the downstream signaling network activation through a positive feedback loop since
LPP has been shown to be recruited to focal adhesions in MDCK epithelial cells, and to interact
with α-actinin to facilitate stress fiber formation.96,105,145 Western blot analyses on
phosphorylation of FAK was determined in MFAP5 treated hMEC-1 and TIME cells transfected
with LPP siRNA or the control siRNA. Results showed that LPP siRNA can successfully
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abrogate MFAP5 induced FAK phosphorylation (Fig. 107). In addition, our data showed that
knockdown of LPP attenuated MFAP5 stimulated increase of focal adhesion (Figs. 87 and 88),
these suggest that focal adhesion targeting by LPP may play an essential role in the formation
of the focal adhesion complexes and the activation of downstream signaling molecules, which
mediate the effect of MFAP5 on endothelial cell motility and permeability.

Fig. 107: Western blots showing the effect of LPP silencing on MFAP5 induced FAK
phosphorylation in microvascular endothelial cells. Knockdown of LPP by LPP-targeting
siRNAs abolished MFAP5-induced FAK phosphorylation at Y861 site in hMEC-1 and TIME
cells compared to those transfected with scramble non-targeting siRNA.
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Specific aim III: Development of MFAP5-targeted therapeutic agents for ovarian cancer
treatment
A. Characterization of anti-MFAP5 antibodies by western blot analysis and epitope
mapping
There is ample evidence to indicate that angiogenesis is important to the development,
progression and poor prognosis of ovarian cancer,146 suggesting that agents targeting the
tumor vasculatures can be used as a therapeutic regimen in the treatment of ovarian cancer
and improve patient survival.
Since our data demonstrated the pro-angiogenic role of MFAP5 in vitro and in vivo, and
showed that targeting stromal MFAP5 by siRNA could suppress ovarian cancer growth and
blood vessel permeability in mice, we have generated MFAP5-targeting monoclonal antibodies
using purified human recombinant MFAP5 protein as antigen. Monoclonal antibodies from 95
hybridoma clones were showed to bind human recombinant MFAP5 (recMFAP5) by ELISA
(data not shown) and western blot analysis using the Bio-rad multiscreen apparatus identified
16 antibody clones with strong binding affinity to human MFAP5 (Fig. 108). 5 clones (50B, 52B,
64A, 75B and 117B) were sent out for epitope mapping and the result showed that all of them
recognize the same human MFAP5 protein sequence [DETVLAVLA] (Fig. 109).

145

Fig. 108: Western blot screening to identify specific anti-MFAP5 antibodies. Western
blot analysis using the Bio-rad multiscreen apparatus to screen for (A) positive clones that
bind to human recombinant MFAP5 protein and (B) 16 clones that have high binding
efficiency to cell lysate from MFAP5 overexpressing fibroblasts, NOF151-LvMFAP5. (Green:
positive control of commercially available polyclonal anti-MFAP5 antibody, Sigma #
HPA010553)
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Fig. 109: Epitope mapping for antibodies specific for human MFAP5. Epitope mapping
data showing that clones 50B, 52B, 64A, 75B and 117B recognize the human MFAP5 protein
sequence [DETVLAVLA].

Next, we used the same screening strategy to screen for anti-mouse MFAP5 clones.
One clone, 130A, was showed to bind both recombinant human and mouse MFAP5 proteins
(Fig. 110). Epitope mapping result showed that clone 130A recognize the MFAP5 protein
sequence [LSRQMAGLPPRRL] (Fig. 111), which is a consensus peptide sequence shared
between human and mouse MFAP5 proteins (Fig. 112).
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Fig. 110: Specificity of clone 64A, 117B and 130A to human and/or mouse MFAP5.
Western blot analyses showing the specificity of two clones of mouse monoclonal antibodies
(64A and 117B) against human MFAP5 only and one clone of antibody (130A) against both
human and mouse MFAP5.

Fig. 111: Epitope mapping for clone 130A anti-MFAP5 antibody. Epitope mapping data
showing that clone 130A recognizes the MFAP5 protein sequence [LSRQMAGLPPRR].
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Fig. 112: Protein sequences of mouse and human MFAP5 showing the epitopes
recognized by the three clones (64A, 117B and 130A) of anti-MFAP5 antibodies. While
clones 64A and 117B recognize on human MFAP5, clone 130A is able to recognize both
human and mouse MFAP5 proteins.

B. Functional assays demonstrated inhibitory effect of anti-MFAP5 antibodies on cell
motility
Functional studies on clones 64A and 117B showed that antibody treatment attenuated
the stimulatory effect of fibroblast-derived MFAP5 on cell motility in both ovarian cancer cells
and endothelial cells (Fig. 113). In addition, clone 130A significantly attenuated the enhanced
motility potential in mouse endothelial cells SVEC4-10 (ATCC #CRL-2181) treated with mouse
recombinant mfap5 protein (Fig. 114).

149

Fig. 113: In vitro functional assay showed inhibitory effects of clones 64A and 117B on
MFAP5 enhanced cell motility. Motility assays were performed on αVβ3 expressing human
ovarian cancer cells A224 and ALST and human microvascular endothelial cell lines hMEC-1
and TIME co-cultured with MFAP5-overexpressing fibroblasts or the control fibroblasts in the
presence of human IgG or anti-human MFAP5 antibody clones 64A and 117B.
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Fig. 114: In vitro functional assay showed inhibitory effects of clone 130A on mouse
mfap5 enhanced mouse endothelial cell motility. Motility assays were performed on
mouse endothelial cells SVEC4-10 cultured in media supplemented with MFAP5 or PBS and
treated with mouse IgG or anti-mouse MFAP5 antibody clone 130A.

C. In vivo animal study showed tumor suppressing effects of clone 130A anti-mfap5
antibody
To further evaluate the feasibility in using the anti-MFAP5 antibodies to target stromal
MFAP5 in vivo, nude mice were injected I.P. with luciferase labeled OVCA432 cells. After one
week, the mice were injected twice weekly with anti-MFAP5 antibody clone 130A (15 mg/kg) or
the control normal mouse IgG (15 mg/kg) (N=12 per group) and tumor progression was
monitored by luciferase based small animal imaging. After six weeks, mice were injected with
FITC-labeled dextran before they were sacrificed (Fig. 115A). Results showed that significant
lower luciferase activity was detected in mice treated with anti-MFAP5 antibody clone 130A
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when compared to the control group treated with control normal mouse IgG (Fig. 115B).
Significant lower tumor weight was observed in anti-MFAP5 antibody treated group when
compared to control group (Fig. 115C). Also ex vivo luminescence data further confirmed the
anti-tumor effect of the antibody (Fig. 115D). In addition, FITC-dextran signals in tumor tissues
were significantly lower in anti-MFAP5 antibody treated group compared to IgG treated group
suggesting that anti-MFAP5 antibody reduced the intratumoral microvessel leakiness (Fig.
116). These data demonstrated that targeting stromal MFAP5 could be a potential therapeutic
approach for ovarian cancer.
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Fig. 115: Anti-MFAP5 antibody clone 130A suppressed ovarian tumor growth in vivo.
(A) A schematic diagram showing the procedures of evaluating the effect of anti-mfap5
antibody treatment in vivo. (B) Tumor volume of each treatment group was quantified by the
IVIS-200 bioluminescence and fluorescence imaging system (Caliper Life Sciences, Inc.,
Hopkinton MA). Significant lower luciferase activity was detected in anti-mfap5 antibody
treated groups compared to the control group. (p=0.004). The box represents the
interquartile range of the records and the line across the box indicates the median. Whiskers
indicate the highest and lowest values among the records that are no greater than 1.5 times
the interquartile range. (C) After necropsy, tumor weight and ex vivo luciferase activity were
recorded for each animal. Results showed a significant reduced tumor dry weight after antimfap5 antibody treatment (p=0.0086). (D) Ex vivo imaging data also demonstrated
significantly lower luciferase activity in the tumor tissue in anti-mfap5 antibody treated group
compared to IgG treated control (p=0.0339). For scatter plots, upper and lower bars indicate
the interquartile range of the records, and the middle line indicates the median.
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Fig. 116: Anti-MFAP5 antibody clone 130A reduced tumor angiogenesis and
intratumoral microvessel leakiness in vivo. Confocal microscopy demonstrating lower
CD34 positive microvessel density (red) and FITC-dextran (green) signals around tumor
microvessels in anti-mfap5 antibody treated mice compared to IgG treated mice. For scatter
plots, upper and lower bars indicate the interquartile range of the records, and the middle line
indicates the median.

D. Evaluation of the effect of clone 130A anti-mfap5 antibody on intratumoral
microvessel leakiness and drug delivery efficiency
To evaluate whether the reduced intratumoral microvessel leakiness by anti-MFAP5
antibody can affect the bioavailability of systemically administrated drugs in ovarian tumors, we
treated OVCA432 bearing mice with control IgG or anti-MFAP5 antibody for 4 weeks. 1 mg/kg
of Oregon Green 488-conjugated paclitaxel (Life Technologies Corp., Grand Island, NY) was
I.V. injected into each of the animals at 1 hour before they were sacrificed. Tumor weight was
recorded and 6 μm frozen tissue sections were prepared from tumor tissues harvested.
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Fluorescent microscopy and immunolocalization of CD34 showed that significant increased
Oregon Green 488-conjugated paclitaxel in the tumor tissue and the density of intratumoral
microvessels were decreased in mice treated with 130A anti-MFAP5 antibody when compared
to control mice treated with IgG (Fig. 117).

Fig. 117: Clone 130A anti-mfap5 antibody facilitated systematic administered
paclitaxel delivery to ovarian tumors. Fluorescent microscopy and immunolocalization of
CD34 (red) showed significant increase of Oregon Green 488-conjugated paclitaxel (green)
was delivered to tumors although intratumoral microvessel density was decreased in mice
treated with 130A anti-mfap5 antibody compared to control mice treated with IgG. For scatter
plots, upper and lower bars indicate the interquartile range of the records, and the middle line
indicates the median.

E. Toxicity test showed no observable adverse effects due to administration of antiMFAP5 antibodies
In addition, toxicity analysis was performed on mice treated with anti-MFAP5 antibodies
clone 64A, 117B, 130A or PBS (N=3/group). Complete blood count (CBC) and chemistry panel
to measure the levels of (1) albumin, (2) alkaline phosphatase (ALP), (3) alanine
aminotransferase (ALT), (4) aspartate aminotransferase (AST), (5) blood urea nitrogen (BUN),
(6) creatinine, (7) globulin and (8) total proteins in serum samples collected were performed.
The eight parameters were selected to evaluate any liver or kidney damage due to the antibody
treatments and no significant toxic effects were observed (Figs. 118 and 119) when compared
155

to the PBS control. In addition, H&E stained organ and tissue sections were evaluated by a
veterinary pathologist and no significant tissue damage was observed (Fig. 120).

Fig. 118: Toxicity test on anti-MFAP5 antibodies by complete blood count. Complete
blood count among clone 64A, 117b or 130A anti-MFAP antibody treated groups compared
to PBS treated control group revealed no observable adverse effects due to administration of
anti-MFAP5 antibodies. For scatter plots, upper and lower bars indicate the interquartile
range of the records, and the middle line indicates the median.
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Fig. 119: Toxicity test on anti-MFAP5 antibodies by chemistry tests. Chemistry tests on
serum collected from clone 64A, 117B or 130A anti-MFAP5 antibody treated group
compared to PBS treated control group revealed no significant toxic effect by the antibody
treatment to the animal’s kidneys and livers. For scatter plots, upper and lower bars indicate
the interquartile range of the records, and the middle line indicates the median.
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Fig. 120: Histological examination to evaluate tissue damages due to anti-MFAP5
antibodies treatment. H&E-stained images from the spleen, kidney and liver tissue samples
from mice treated with clone 64A, 117B or 130A anti-MFAP5 antibody compared to PBS
treated control group for 2 weeks. No significant toxic effects were observed. Representative
images were selected from three individual replicates.
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In the tumor microenvironment, the dynamic and reciprocal interactions among cells,
the extracellular matrix, and soluble molecules dictate tumor progression.147 As one of the key
cell types that modulate cancer progression in the tumor microenvironment, CAFs have higher
proliferation rates than normal fibroblasts and often have enhanced production of collagen,
hyaluronate and epithelial growth factors.148,149 Researchers have demonstrated that CAFs that
secrete chemokines at elevated levels promote the initiation and development of ovarian
cancer.50 Furthermore, the complex stromal microenvironment has made therapeutic
elimination of cancer impossible for decades.2
In the present study, we identified a stromal gene signature for HGSOC using
microdissected tumor samples and found that CAF-derived MFAP5 is a prognostic marker of
poor ovarian cancer patient survival. MFAP5 is involved in elastic microfibril assembly and
modulates endothelial cell behavior.72,150 Focusing on the epithelial component of HGSOC, our
group previously identified MFAP5 as a survival-associated gene in HGSOC. We observed
MFAP5 amplification and overexpression in a small percentage of advanced HGSOC cases.75
In addition, we found that ovarian cancer-derived MFAP5 promoted tumor cell survival and
stimulated endothelial cell motility and survival via the αVβ3 integrin receptor. However, to our
surprise, transcriptome profiling of the microdissected stromal component of HGSOCs revealed
that CAFs had much higher expression of MFAP5 mRNA than did the normal ovarian stroma
and epithelial components of ovarian tissue. In addition, immunolocalization of MFAP5 using a
newly available polyclonal antibody confirmed that ovarian cancer stroma indeed has markedly
higher levels of MFAP5 expression than did the epithelial component, which we did not observe
in our previous study. The discrepancy is likely due to the fact that stromal MFAP5 may be
cross-linked with other proteins in the stroma more tightly during the formalin fixation process
and requires higher antigen retrieval temperatures to re-expose the epitope recognized by the
antibodies that have higher affinity to MFAP5. To strengthen the significance of CAFs as
source of MFAP5 in the tumor microenvironment, western blot analyses on samples from
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immortalized CAFs, primary CAFs, as well as HGSOC cell lines were also performed. While
some HGSOC cell lines express a detectable amount of MFAP5, our data confirmed that CAFs
are the major sources of MFAP5 in the ovarian tumor microenvironment. In addition, in cases
which tumor cells have low levels of MFAP5 expression but high levels of stromal MFAP5
expression, stromal MFAP5 secreted from CAFs may exert a paracrine effect on ovarian
cancer cells and contribute to ovarian tumor progression. Our correlation studies showed that
epithelial and stromal MFAP5 expressions in tumor tissue were significantly associated with
each other. Therefore, it is not a surprise to find out that high levels of stromal MFAP5
expression, similar to the epithelial MFAP5 expression as reported in the previous study, were
also significantly associated with poor patient survival. The significant association between
stromal and epithelial MFAP5 expression suggests that MFAP5 is regulated by certain tumor
microenvironmental cues in the same manner. However, the molecular mechanism by which
stromal MFAP5 is expressed at high levels remains to be elucidated.
Our in vitro data demonstrated a significant increase in cell motility and invasion
potential but not cell proliferation after treatment with recombinant MFAP5 protein in both
ovarian cancer cells and microvascular endothelial cells. To evaluate the role of CAF-derived
MFAP5 on ovarian cancer cell migration and invasion potentials in vivo, we developed a new
model that allows the interaction between MFAP5-secreting CAFs and cancer cells in the
intraperitoneal microenvironment. In this model, a Matrigel plug embedded with MFAP5secreting CAFs recapitulates a substratum through which ovarian cancer cells invade MFAP5expressing CAFs in the tumor. The results of our study using this model demonstrated that
Matrigel plugs with MFAP5 represent a better soil for cancer cells to invade. Similarly, an in
vivo angiogenesis assay was performed and enhanced formation of endothelial cell network
was observed in recombinant MFAP5 containing matrigel plugs implanted subcutaneously into
mice. Effects of MFAP5 on cancer metastasis was further evaluated by injecting MFAP5specific siRNA-encapsulated nanoparticles into an orthotopic model in which ovarian cancer
161

cells were directly injected into the ovary. The significantly decreased in the number of
metastatic nodules, the organs involved and intratumoral microvessel density in MFAP5 siRNAtreated mice compared with the control, suggesting the therapeutic potential of targeting
stromal MFAP5 as a new treatment modality, which may inhibit disease progression and
improve survival.
Since the N-terminal of MFAP5 contains an RGD motif which binds to αVβ3 integrin
receptor and integrin-mediated FAK signaling promotes cell motility has been well
documented,151-153 we therefore tested whether MFAP5 promoted ovarian cancer cell and
endothelial cell motility via FAK phosphorylation. Interestingly, instead of the best-characterized
FAK phosphorylation event at Tyr397,154 we observed significant increase of FAK
phosphorylation at Tyr861. Phosphorylation of FAK at Tyr861 has been reported to regulate
migration and metastatic potential of prostate and breast cancer cells.155,156 It is also crucial for
RAS transformation of fibroblasts as well as migration and survival of vascular endothelial
cells.134,157 Although it is commonly believed that phosphorylation of FAK at Tyr397, which
creates a motif that is recognized by various SH2-domain containing proteins such as Src, is a
prerequisite for FAK phosphorylation at additional tyrosine sites, recent evidence suggested
that FAK Tyr861 phosphorylation can be Src and Tyr397 phosphorylation independent.157-160 In a
study on colon cancer cell line KM12C, phosphorylation of FAK at Tyr407, Tyr566, Tyr567 and
Tyr861, which previously attributed to Src kinase activity, was shown to be mediated by a
functional Src Homology 2 (SH2) domain instead of by the Src kinase.159 In addition, recent
studies on RAS-transformed cells indicate that phosphorylation of FAK at Tyr861 promotes its
association with CRK-associated substrate (CAS, also known as p130cas) and recruitment of a
CRK-DOCK 180-ELMO complex (DOCK 180: Dedicator of cytokinesis of 180kDa; ELMO:
Engulfment and cell motility protein) that activates RAC1, subsequently activating JUN Nterminal kinase (JNK) that promotes MMP expression and cell invasion.157 We therefore
hypothesize that the binding of MFAP5 to αVβ3 integrin might modulate downstream signaling
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for cell migration and invasion via regulation of the interactions between FAK and other SH2domain-containing proteins. Indeed, a detailed bioinformatics examination of SH2 domains
reveals 120 SH2 domains in 110 proteins encoded by the human genome, suggesting that
other potential SH2 domain-containing proteins instead of Src may be involved in the MFAP5mediated FAK Tyr861 phosphorylation.161 Further investigation on which particular SH2 domain
containing-protein is involved in the MFAP5-integrin signaling transduction may identify a new
mechanism of how FAK phosphorylation promotes cell migration and invasion.
On the other hand, our findings demonstrated that Ca2+ mobilization is essential for
MFAP5’s effects on ovarian cancer and endothelial cell motility and invasion potential. Ca2+
plays a multifunctional role in regulating cell migration, including cytoskeleton redistribution and
focal adhesion relocation.90,162-164 Five major classes of membrane Ca2+-permeable channels
are known to be differentially expressed in various cell types although there are other channels
recently proposed.82,165 First, voltage-gated calcium channels which are activated by
depolarizing membrane potentials and expressed mostly in excitable cells. Second, the ligandgated channels mainly involved in fast chemical synaptic transmission in the nervous system.
Third, transient receptor potential channels that mediate Ca2+ entry through a large variety of
gating mechanisms, including stretching of plasma membrane. Fourth, store-operated calcium
(SOC) channels that required calcium release-activated calcium channel protein 1 (ORAI1) and
stromal interaction molecule 1 (STIM1) to function. SOC channels are the major Ca2+ entry
pathways in non-excitable cells and are widely distributed in various cell types. Finally,
arachidonate-regulated Ca2+ (ARC) entry channels which are activated in response to receptormediated derivation of arachidonic acid.
The present study demonstrated that treatment with an L-type voltage-gated Ca2+
channel blocker attenuated MFAP5-induced calcium influx but did not abolish this effect,
whereas treatment with an L-type voltage-gated Ca2+ channel opener successfully stimulated
calcium entry in ALST cells, suggesting that MFAP5 triggers exogenous Ca2+ entry into cells
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via the L-type voltage-gated channel, although other channels may be involved. Treatment with
an IP3 receptor inhibitor but not a ryanodine receptor blocker attenuated MFAP5-induced
calcium mobilization, suggesting that MFAP5 induces calcium release via the IP3 receptor
instead of the ryanodine receptor. This was supported by our finding that MFAP5 activates
PLC-γ1 phosphorylation, which may lead to hydrolysis of intracellular phosphatidylinositol-4, 5biphosphate to IP3 and DAG. IP3 binds to its receptor, causing Ca2+ release from the
endoplasmic reticulum.77,82
Calcium is a prominent regulator of cell migration, exerting multiple effects on the
contractility of the actin cytoskeleton.115,166 Our findings of abrogation of MFAP5-induced actin
rearrangement, stress fiber condensation, and traction force induction by BAPTA/AM,
suggested that calcium-dependent actin reorganization, together with increased traction force
modulate MFAP5’s motility and invasion promoting effects. Of note, for a typical human cell,
the cytoplasmic free Ca2+ concentration ([Ca2+]c) is maintained at about 100nM, a very low level
relative to the extracellular fluid ([Ca+]Ec≈1.2mM).167 Upon stimuli activation, [Ca2+]c will rise to
500-1000nM due to the entry of external Ca2+ or the release of Ca2+ from internal stores.77 On
the other hand, the off mechanisms composed of pumps and exchangers that will remove Ca2+
from the cytoplasm and restore the resting state. In the case of calcium accumulation and
mitochondrial Ca2+ uptake, apoptosis may take place.167-169 However, treatment of ovarian
cancer cells and microvascular endothelial cells with recombinant MFAP5, which triggered
transient and partial discharge of Ca2+ from the ER store at nanomolar level, should not induce
a stress condition that initiates apoptosis.
Regarding MFAP5 induced ovarian cancer cell motility and invasion potential, we have
identified TNNC1 as the effector molecule of such cancer cell phenotypes. TNNC1 contains a
calcium-binding subunit and facilitates the interaction between actin and myosin in muscle cells
and the formation of stress fibers.170 Indeed, troponin is expressed not only in striated muscle
cells but also fibroblasts.93 In nonmuscle cells, TNNC1 may not serve as a structural protein but
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rather as a regulatory protein for cellular locomotion, cytoplasmic streaming, and cytokinesis.170
In the present study, we have demonstrated TNNC1 upregulation in MFAP5 treated epithelial
ovarian cancer cells and that siRNA silencing of TNNC1 abolishes MFAP5’s stimulatory effect
on cancer cell motility. This is the first study to demonstrate that increased TNNC1 expression
modulates epithelial cancer cell motility and invasion potential via cytoskeleton reorganization.
In addition, immunolocalization of TNNC1 on HGSOC samples demonstrated the positive
correlation between cancer cell TNNC1 expression and stromal MFAP5 expression and the
association between increased TNNC1 expression and poor survival. These data confirmed
that TNNC1 is the effector protein for stromal MFAP5, which can promote cell motility and
invasion potential via tumor-stromal crosstalk and subsequently affect clinical outcome. Of
note, we observed that TNNC1 silencing did not affect ovarian cancer cell proliferation,
suggesting that the effect of MFAP5 on tumor growth we observed in vivo is indirect, most likely
via its effect on other cell types in the microenvironment. This can be explained by the data
obtained from aim 2 of this study, which we demonstrated a pro-angiogenic role of MFAP5 that
enhanced intratumoral microvessel density and subsequently lead to increased tumor growth in
vivo.
Our mechanistic studies demonstrated that both stimulatory effects of MFAP5 on
ovarian cancer cells and microvascular endothelial cells share similar calcium dependent
signaling pathways via upregulation of p-FAK, p-PLCγ1, p-PKCθ, p-ERK1/2, p-CREB, c-Jun
and p-c-Jun. Yet, TNNC1 expression was not detected in both control and MFAP5 treated
hMEC-1 and TIME cells by qRT-PCR, suggesting that the stimulatory effect of MFAP5 does not
share the same effector molecule in ovarian cancer cells and microvascular endothelial cells.
Further microarray analysis on endothelial cells invaded into Matrigel plug identified
upregulation of Lipoma-Preferred Partner (LPP), an actin cytoskeleton protein that is
associated with calcium signaling, in microvessels infiltrating the Matrigel reconstituted with
MFAP5 compared to those with PBS and in hMEC-1 and TIME cells treated with exogenous
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MFAP5. Immunofluorescent microscopy indicated MFAP5 induced increased LPP expression
particularly in the focal adhesions at the cell periphery, which strongly support its role in cell
motility. Furthermore, transfecting LPP siRNAs into MFAP5 treated endothelial cell lines hMEC1 and TIME abrogated the effect of MFAP5 on cell motility, suggesting that LPP is a key
downstream effector molecule for MFAP5 in controlling endothelial cell motility. Further
analyses on MFAP5 treated endothelial cells showed that MFAP5 mediated the formation of
focal adhesion complexes through regulation of LPP.
Another novelty of this project is that anti-MFAP5 monoclonal antibodies were
developed and tested as a therapeutic agent for ovarian cancer treatment. By western blot
analyses, we identified two clones of mouse monoclonal antibodies (64A and 117B) against
human MFAP5 only and one clone of antibody (130A) against both human and mouse MFAP5.
While all three antibody clones demonstrated inhibitory effects on cancer cell and endothelial
cells motility in vitro, clone 130A was chosen for further in vivo evaluation using orthotopic
mouse model due to its ability to recognize and target MFAP5 protein derived from mouse
stromal fibroblasts. Our in vivo data demonstrated suppressed ovarian tumor progression and
tumor angiogenesis by targeting stromal mfap5 using clone 130A with no observable toxicity,
suggesting that targeting stromal MFAP5 may improve therapeutic benefit from anti-angiogenic
strategies in ovarian cancer patients. This is exciting as MFAP5 is only detected at medium
level in 1/81 normal tissue samples compared to the extensively studied VEGF, which has high
or medium expression level in 75/80 analyzed normal tissue samples (The Human Protein
Atlas). Therefore, reduce drug-associated side effects could be expected.
As described in the introduction, tumor vasculatures were found to be both functionally
and structurally abnormal with decreased perfusion and increased leakiness.64 Vessel
normalization is therefore being proposed by a number of research groups as a mean to
restore vessel functions and integrity, which could subsequently facilitates delivery of cancer
therapeutic agents.60,171 Vessel normalization could be achieved by using anti-angiogenic
166

agents that inhibit uncontrolled angiogenesis and favor the formation of structurally normal
vessels. Since our experimental results suggested that MFAP5 induced motility and traction
force generation of endothelial cells, we further analyzed the effects of MFAP5 treatment on the
integrity of endothelial cell monolayer cultures. Endothelial cell monolayers treated with MFAP5
protein demonstrated increased leakiness and therefore suggested that targeting MFAP5 in the
tumor microenvironment could potentially facilitate vessel normalization. We therefore
evaluated the effect of targeting stromal MFAP5 by monoclonal antibodies on tumor vessel
leakiness and chemotherapeutic agent delivery. Experimental results demonstrated that tumor
tissues harvested from MFAP5-targeting antibody clone 130A treated mice had reduced vessel
leakiness and increased bioavailability of paclitaxel, suggested that targeting stromal MFAP5
by monoclonal antibodies could facilitate tumor inhibition via vessel normalization.
Since increased paclitaxel bioavailability in tumor tissues was observed in MFAP5targeted animals, therefore we would like to propose to study whether targeting stromal MFAP5
by the monoclonal antibodies could potentiate the effect of therapeutic efficacy of
chemotherapy for ovarian cancer treatment in the future. Combination of MFAP5-targeting
therapy and chemotherapy could be beneficial with two possible mechanisms: 1) By
normalizing the vascular permeability: Anti-MFAP5 antibodies could allow better tumor
perfusion, and thus chemo drugs will be delivered to the tumors more efficiently.172 2) The
dividing, genetically stable endothelial cells of newly forming tumor vessels are believed to be
sensitive to chemo drugs and the anti-angiogenic anti-MFAP5 antibodies may enhance this
sensitivity.171,173,174 It is believed that targeting the whole tumor organ and not just its epithelial
component would benefit patients and increase survival.45,175 Indeed, our data showing
increased paclitaxel delivery (Fig. 118) after treating ovarian tumors with anti-MFAP5
monoclonal antibody clone 130A in line with proposed mechanism 1 provided a strong
background for us to explore the synergistic effect of combining paclitaxel with anti-MFAP5
monoclonal antibody for ovarian cancer treatment.
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Drug combinations is widely used in cancer therapies and there is an increasing
awareness that the use of synergistic drug combinations in treating cancer allows lower doses
of each constituent drug and consequently reduces toxicity and minimize or delay the induction
of drug resistance.176,177 However, when two or more therapeutic agents are given in
combination, it is possible that instead of a superadditive (synergistic) effect, subadditivity or
simply additivity may be observed. To address this, the Chou-Talalay combination index
theorem offers quantitative definition for additive effect (combination index = 1), synergism
(combination index < 1) and antagonism (combination index > 1) in drug combinations.178 In
addition, based on the concept of dose equivalence, the isobolographic analysis provides the
mathematical basis for assessing synergy and an optimization strategy for determining the
dose combination.177,179 A straight line connecting the dose pairs on the x- and y-axes when
there is no interaction between the drugs is called an isobole. The isobole allows the
assessment of superadditive and subadditive interactions when actual combination doses are
tested. If a dose pair that plots as a point below the isobole, this means that the effect was
attained with doses less than those on the line, a situation that denotes superadditivity or
synergism. In contrast, if a dose pair plots as a point above the isobole line, this indicates a
greater combination doses are required to generate the specified effect and therefore depicting
a subadditive (antagonism) situation. For dose pairs that experimentally lie on the isobole, the
term additive applied showing a situation that there is no interaction between the two drugs.
However, the prerequisite for all drug combination studies is the dose-effect curves for each
single drug. For our in vivo studies using monoclonal antibodies to target stromal MFAP5, a
single dosage design was used. While it served well in demonstrating the therapeutic potential
of targeting MFAP5 in ovarian cancer, in order to explore the synergistic effect of combining
paclitaxel with anti-MFAP5 monoclonal antibody for ovarian cancer treatment,

dose-effect

curves for both anti-MFAP5 monoclonal antibody and paclitaxel using a range of different
treatment dosages will need to be generated. In addition, further evaluating the therapeutic
efficacy of MFAP5-targeting monoclonal antibodies with a range of dosages using animal
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models will allow us to determine the optimal antibody dosage and vessel normalization
window for the MFAP5-targeting anti-angiogenic therapy for ovarian cancer. It is believed that
optimizing drug dosage and finding the suitable vessel normalization window is crucial because
sustained or aggressive antiangiogenic regimens may prune away tumor vessels, resulting in a
vasculature that is both resistant to further treatment and inadequate for the delivery of drugs
and oxygen.35,60,65 Under hypoxic conditions, radiation therapy and a subset of chemotherapy
drugs that require oxygen to kill tumor cells are ineffective. In addition, immune cells, which
might help fight cancer cells, are hampered by high acidity and low oxygen.35,64
Moreover, the dosing schedule may play an important role in both vessel normalization
and the effects of drug combination. In the present study, tumor shrinkage and reduced
intratumoral microvessel density were observed by treating tumor bearing mice with antiMFAP5 antibody twice weekly for 6 weeks. However, it would be favorable if similar therapeutic
effects could be observed using a less frequent drug administration schedule as antibodies are
generally considered as stable drugs and patients may save their trips to the hospital for
injections. For drug combination, we might pre-treat tumor bearing mice with anti-MFAP5
monoclonal antibody for one to two weeks before the combination drug treatment with
paclitaxel. The rationale behind is to normalize the pathologic tumor vasculature, i.e. reduces
intratumoral vessel leakiness, decreases interstitial fluid pressure and increases intratumoral
blood flow, for optimal uptake of paclitaxel when it is injected into the mice. On the other hand,
the duration of the combination treatment may also be optimized. The concept of metronomic
chemotherapy suggested that administering comparatively low doses of chemotherapy drugs
on a frequent or continuous schedule, with no drug-free breaks might enhance the antiangiogenic efficacy of conventional cytotoxic chemotherapeutics and facilitate tumor response
toward combination therapy of anti-angiogenic drugs and chemotherapy. It stands as a different
philosophy from the maximum tolerated dose (MTD) method typically used but it might serve to
reduce acute toxicity and the development of drug resistance.180 After the optimal dosage and
169

dosing schedule of MFAP5-targeting monoclonal antibodies have been identified, to move
forward, preclinical toxicity test will be performed on rhesus monkey because MFAP5 protein in
rhesus monkey and human shared a 98.24% homology. Rhesus monkeys will be dosed at two
dose levels with optimized dosing schedule. In life testing such as hematology, clinical
chemistry, urinalysis, coagulation, bone marrow evaluation will be performed. In addition,
anatomic pathology after necropsy will be performed to determine any adverse effects made to
the major organs due to the antibody treatment. If satisfactory result could be obtained from the
preclinical toxicity test, human clinical trial would be the next step to evaluate the therapeutic
potential of using anti-MFAP5 monoclonal antibody to target stromal MFAP5 for ovarian cancer
treatment. Humanized anti-MFAP5 monoclonal antibodies may be developed to decrease the
murine components and reduce the risk of developing human anti-mouse antibody (HAMA),
which may cause a mild allergic reaction such as a rash to a more extreme and life-threatening
situation like renal failure.181,182 These humanized or chimarized monoclonal antibodies have a
longer half-life in the patients’ blood stream, and enables better interactions with human
effector cells in the patients’ bodies.181
To increase the potency of the monoclonal antibody, the humanized anti-MFAP5
antibody could be modified as immunoconjugate therapy by conjugating with drugs, toxins and
radioisotopes to carry enhanced killing capacity directly to the tumors.181,183 Further, we could
determine the sequence of the light and heavy chains (LV and HV) of the variable region of the
anti-MFAP5 antibody developed, and use the single chain variable fragment (scFv) technology
to develop scFv multimers as described,184 which will potentially increase the affinity of the
antibody to MFAP5.
In conclusion, we found that CAF-derived MFAP5 modulated motility and invasion
potential in ovarian cancer cells and microvascular endothelial cells and promoted tumor
angiogenesis via the calcium signaling pathway (Fig. 121). Targeting stromal MFAP5 with antiMFAP5 monoclonal antibody markedly decreased tumor growth and metastasis in vivo,
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suggesting that it is a new treatment modality for ovarian cancer. The possible modifications of
the anti-MFAP5 monoclonal antibody predict a more specific and less toxic therapy for ovarian
cancer treatment in the future. More importantly, this study demonstrated the possibility of
targeting/ reprogramming CAF-derived tumor-promoting factors to inhibit tumor progression,
thereby presenting an alternative approach to the treatment of cancer.185 We believe that
targeting CAFs in the tumor microenvironment may synergize with other cancer cells-targeting
treatment regimens to increase treatment efficacy.

Fig. 121: The overall mechanism by which stromal MFAP5 stimulates ovarian cancer
progression, metastasis and tumor angiogenesis. Stromal MFAP5, which is significantly
upregulated in ovarian CAFs, activates the calcium-dependent signaling pathways in cancer
and endothelial cells via the engagement of the αVβ 3 integrin receptor. This figure
summarized the roles of MFAP5 in tumor progression through enhancing cancer cell
metastasis and promoting tumor angiogenesis.
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